0001493152-17-008925.txt : 20170811 0001493152-17-008925.hdr.sgml : 20170811 20170811060241 ACCESSION NUMBER: 0001493152-17-008925 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170811 DATE AS OF CHANGE: 20170811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CombiMatrix Corp CENTRAL INDEX KEY: 0001383183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 470899439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33523 FILM NUMBER: 171022884 BUSINESS ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-753-0624 MAIL ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended June 30, 2017

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO .

Commission File Number 001-33523

COMBIMATRIX CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware		47-0899439
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

310 Goddard, Suite 150,
Irvine, CA		92618
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 753-0624

N/A

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]

Accelerated filer [ ]

Non-accelerated filer [ ]
(Do not check if a smaller
reporting company)

Smaller reporting company [X]

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

As of August 7, 2017, 2,918,726 shares of CombiMatrix Corporation common stock, $0.001 par value were issued and outstanding.

COMBIMATRIX CORPORATION

Table of Contents

Part I. Financial Information

Item 1.	Financial Statements (Unaudited)

	Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016	3

	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 and 2016	4

	Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2017 and 2016	5

	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016	6

	Notes to Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23

Item 4.	Controls and Procedures	23

Part II. Other Information

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mine Safety Disclosures	26

Item 5.	Other Information	26

Item 6.	Exhibits	26

Signatures		27

Exhibit Index		28

Part I. Financial Information

Item 1. Financial Statements (Unaudited)

COMBIMATRIX CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

	June 30,			December 31,
	2017			2016
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,022		$	2,727
Short-term investments		-			1,000
Accounts receivable, net of allowance for doubtful accounts of $227 and $232		4,006			3,351
Supplies		368			599
Prepaid expenses and other assets		170			174
Total current assets		7,566			7,851
Property and equipment, net		523			597
Other assets		30			30
Total assets	$	8,119		$	8,478

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable, accrued expenses and other	$	1,920		$	1,689
Current portion, long-term debt		49			100
Total current liabilities		1,969			1,789
Capital lease obligations, net of current portion		72			50
Deferred rent		126			145
Total liabilities		2,167			1,984

Commitments and contingencies (Note 6)

Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 92 and 969 issued and outstanding		-			-
Common stock; $0.001 par value; 50,000,000 shares authorized; 2,918,726 and 2,673,756 shares issued and outstanding		15			15
Additional paid-in capital		109,471			109,068
Accumulated other comprehensive loss		-			-
Accumulated deficit		(103,534	)		(102,589	)
Total stockholders' equity		5,952			6,494
Total liabilities and stockholders' equity	$	8,119		$	8,478

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share information)

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Revenues:
Diagnostic services	$	4,214		$	3,049		$	7,972		$	5,979
Royalties		27			58			56			100
Total revenues		4,241			3,107			8,028			6,079

Operating expenses:
Cost of services		1,632			1,432			3,140			2,851
Research and development		85			149			170			292
Sales and marketing		1,016			1,141			2,038			2,477
General and administrative		1,855			1,586			3,519			3,112
Patent amortization and royalties		25			25			50			50
Total operating expenses		4,613			4,333			8,917			8,782
Operating loss		(372	)		(1,226	)		(889	)		(2,703	)
Other income (expense):
Interest income		5			8			11			12
Interest expense		(3	)		(17	)		(10	)		(35	)
Total other income (expense)		2			(9	)		1			(23	)
Net loss	$	(370	)	$	(1,235	)	$	(888	)	$	(2,726	)

Deemed dividend from issuing Series F convertible preferred stock and warrants	$	-		$	-		$	-		$	(1,877	)
Deemed dividend paid for right to repurchase Series E convertible preferred stock		-			-			-			(656	)
Deemed dividend from issuing and modifying Series E convertible preferred stock and warrants		-			-			-			890
Net loss attributable to common stockholders	$	(370	)	$	(1,235	)	$	(888	)	$	(4,369	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.89	)	$	(0.31	)	$	(2.43	)
Deemed dividend from issuing Series F convertible preferred stock		-			-			-			(1.67	)
Deemed dividend paid for right to repurchase Series E convertible preferred stock		-			-			-			(0.58	)
Deemed dividend from issuing and modifying Series E convertible preferred stock		-			-			-			0.79
Basic and diluted net loss per share attributable to common stockholders	$	(0.13	)	$	(0.89	)	$	(0.31	)	$	(3.89	)

Basic and diluted weighted average common shares outstanding		2,915,303			1,382,019			2,838,521			1,122,975

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except share and per share information)

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Net loss	$	(370	)	$	(1,235	)	$	(888	)	$	(2,726	)
Unrealized gain on available-for-sale investments		-			-			-			2
Total comprehensive loss	$	(370	)	$	(1,235	)	$	(888	)	$	(2,724	)

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended
	June 30,
	2017			2016
Operating activities:
Net loss	$	(888	)	$	(2,726	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization		122			130
Non-cash stock compensation		346			405
Provision for bad debts		301			205
Changes in assets and liabilities:
Accounts receivable		(956	)		(687	)
Supplies, prepaid expenses and other assets		235			(22	)
Accounts payable, accrued expenses and other		233			151
Net cash flows from operating activities		(607	)		(2,544	)

Investing activities:
Purchases of property and equipment		(23	)		(147	)
Proceeds from sale of property and equipment		19			-
Purchase of available-for-sale investments		(1,499	)		(4,998	)
Sale of available-for-sale investments		2,499			7,748
Net cash flows from investing activities		996			2,603

Financing activities:
Proceeds from issuance of Series F convertible preferred stock and common stock warrants		-			8,000
Costs from issuance of Series F convertible preferred stock and common stock warrants		-			(1,048	)
Repurchase of Series E convertible prefered stock and dividends		-			(2,842	)
Repayments of long-term debt		(94	)		(95	)
Net cash flows from financing activities		(94	)		4,015

Change in cash and cash equivalents		295			4,074
Cash and cash equivalents, beginning		2,727			653
Cash and cash equivalents, ending	$	3,022		$	4,727

Non-cash financing activities:
Property and equipment purchased under capital lease	$	63		$	6
Adjustments to paid-in capital and retained earnings from change in accounting principle	$	57		$	-
Deemed dividends from issuing Series E convertible preferred stock	$	-		$	(890	)
Deemed dividends from issuing Series F convertible preferred stock	$	-		$	1,877
Accrued public offering costs	$	-		$	10
Accrued property, plant and equipment	$	-		$	20

The accompanying notes are an integral part of these consolidated financial statements.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. OVERVIEW AND BACKGROUND

CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In August 2007, we split-off from Acacia and became publicly traded on The NASDAQ Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.

Description of the Company

We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism, or SNP, chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high-quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.

We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and notes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016, as reported by us in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2017. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of June 30, 2017, and results of operations and cash flows for the interim periods presented. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the entire year.

Going Concern Analysis

We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. As a result, these conditions raise substantial doubt regarding our ability to continue as a going concern beyond twelve months from the date of this filing. However, as of June 30, 2017, we had cash, cash equivalents and short-term investments of $3.0 million. Also, the combination of continued revenue and cash reimbursement growth we have experienced over the past several quarters, coupled with improved gross margins and cost containment of expenses leads management to believe that it is probable that our cash resources will be sufficient to meet our cash requirements for current operations through and beyond the fourth quarter of 2017, when we anticipate achieving cash flow break-even status. If necessary, management also believes that it is probable that external sources of debt and/or equity financing could be obtained based on management’s history of being able to raise capital coupled with current favorable market conditions. As a result of both management’s plans and current favorable trends in improving cash flow, we believe the initial conditions which raised substantial doubt regarding our ability to continue as a going concern have been alleviated. Therefore, the accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and on terms acceptable to us, or at all.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. While we believe in the viability of our strategy to generate sufficient revenue and cash reimbursement, control costs and our ability to raise additional funds if necessary, there can be no assurances to that effect. Our ability to continue as a going concern is dependent upon our ability to further implement our business plan, generate sufficient revenues and cash reimbursement and to control operating expenses.

Risks

Our business operations are also subject to certain risks and uncertainties, including:

	●	market acceptance of our services;

	●	technological advances that may make our services obsolete or less competitive;

	●	increases in operating costs, including costs for supplies, personnel and equipment;

	●	variability in third-party reimbursement of our tests;

	●	the availability and cost of capital; and

	●	governmental regulation that may restrict our business.

Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned services, could have a material adverse effect on our business and operating results.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including third-party commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for any of the periods presented.

Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.

Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.

Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.

Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from Insurance Carrier A of $602,000 exceeded 10% of our total accounts receivable balance as of June 30, 2017. Accounts receivable from Insurance Carrier B of $441,000 exceeded 10% of our total accounts receivable balance as of December 31, 2016.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.

Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.

Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.

Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock as reported on The NASDAQ Capital Market on the date of grant.

In March 2016, the Financial Accounting Standards Board (“FASB”) issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award or recognize forfeitures at the time an award is canceled and forfeited. The standard became effective for us on January 1, 2017. We elected to change our policy regarding forfeitures to recognize if and when an award is canceled and forfeited rather than estimating forfeitures up front. The impact from implementing this policy change was to reduce retained earnings and increase additional paid-in capital by $57,000.

Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Cost of services	$	9	$	4	$	18	$	20
Research and development		-		-		-		-
Sales and marketing		16		17		34		44
General and administrative		128		169		294		341
Total non-cash stock compensation	$	153	$	190	$	346	$	405

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Common stock options		64,326		71,749		64,326		71,749
Restricted stock units		98,049		59,000		98,049		59,000
Common stock warrants		2,701,647		2,701,747		2,701,647		2,701,747
Series F preferred stock convertible into common stock		23,738		1,247,530		23,738		1,247,530
Excluded potentially dilutive securities		2,887,760		4,080,026		2,887,760		4,080,026

Segments. We have determined that we operate in one segment for financial reporting purposes.

Recent Accounting Pronouncements. In July 2017, the FASB issued an accounting standards update regarding earnings per share, distinguishing liabilities from equity and derivatives and hedging. Part 1 of the update addresses the complexity of accounting for certain financial instruments with down-round features, such as anti-dilution provisions of common stock warrant contracts that can require liability classification and subsequent mark-to-market accounting for these securities. As a result of this update, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, which means that derivative accounting treatment and liability classification are no longer required. The amendment requires the effect of a down round feature to be treated as a dividend and as a reduction of income available to common shareholders when computing basic earnings per share when the feature is triggered. In addition, convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features, including related EPS guidance. Part II of the update addresses certain content that is pending or deferred and has no accounting effect. The amendments in Part I of the update are effective for all public entities for the first interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. We are currently analyzing the details of the update and have not yet determined what impact, if any, the adoption of this update may have on our consolidated financial statements.

In May 2017, the FASB issued an accounting standards update regarding stock-based compensation. The purpose of the update is to provide clarity regarding when an entity should apply modification accounting from changes that an entity makes to the terms or conditions of share-based payment awards. The update is effective for all entities for the first interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued a new accounting standard that eliminates Step 2 of the goodwill impairment test currently required under GAAP. Instead, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill that had been allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. This standard is effective for public business entities for the first interim and annual reporting periods beginning after January 1, 2020, with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.

Also in January 2017, the FASB issued a new accounting standard that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. This update is effective on January 1, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

In November 2016, the FASB issued new accounting guidance governing restricted cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The amendments in this guidance should be applied using a retrospective transition method to each period presented. This guidance is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.

In August 2016, the FASB issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.

In February 2016, the FASB issued a new accounting standard regarding leases, which requires lessees to recognize on their balance sheets a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The standard also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The standard requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The standard is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this standard will have on our consolidated financial statements.

In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.

In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We have nearly completed our detailed assessment of the impact that this guidance will have on our consolidated financial statements, with additional analysis currently ongoing. Based on our current assessment, we expect the majority of the amounts that have historically been recognized as bad debt expense, primarily related to patient responsibility, will be reflected as a reduction of the transaction price originally recognized and therefore as a reduction in revenue. We will adopt the new guidance beginning January 2018.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

3. CASH AND SHORT-TERM INVESTMENTS

As of June 30, 2017, we held $3.0 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands):

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

	As of June 30, 2017								As of December 31, 2016
			Unrealized				Fair				Unrealized				Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses		Value

Cash and money market securities	$	1,772	$	-	$	-	$	1,772	$	2,727	$	-	$	-	$	2,727
Commercial paper		500		-		-		500		500		-		-		500
Certificates of deposit		750		-		-		750		500		-		-		500
	$	3,022	$	-	$	-	$	3,022	$	3,727	$	-	$	-	$	3,727

There were no realized gains or losses for the periods ended June 30, 2017 or 2016.

4. FAIR VALUE MEASUREMENTS

The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2017 and December 31, 2016 and the classification by level of input within the fair value hierarchy defined above (in thousands):

			Fair Value Measurements
June 30, 2017	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	2,092	$	842	$	1,250	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	2,092	$	842	$	1,250	$	-

			Fair Value Measurements
December 31, 2016	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	1,735	$	1,735	$	-	$	-
Short-term investments		1,000		-		1,000		-
Cash equivalents	$	2,735	$	1,735	$	1,000	$	-

The carrying amounts of accounts receivable, accounts payable, accrued expenses, capital leases and the secured promissory note approximate fair value due primarily to the short-term nature of these financial instruments.

5. STOCKHOLDERS’ EQUITY

Series A through E Convertible Preferred Stock and Warrant Financings

Between 2012 and 2015, we executed several financing transactions whereby we issued convertible preferred stock and warrants to purchase common stock to investors. As of December 31, 2016, none of the Series A through E convertible preferred stock remained outstanding. For as long as the Series A warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at a price per share below the $73.65 exercise price of the Series A warrants, unless waivers from the Series A investors are obtained. Until the time that less than 7.5% of the Series B, C and E warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at prices per share below the $29.55, $29.55 and $32.51 exercise prices of the Series B, C and E warrants, respectively, unless waivers from the Series B, C and E investors are obtained. In addition, until there are no longer Series A, C and E warrants outstanding, we may not sell any variable rate securities except for certain exempt issuances.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Series E Modifications

On February 4, 2016, we entered into a Series E 6% Convertible Preferred Stock Repurchase Agreement (the “Repurchase Agreement”) with the Series E Investors. Pursuant to the terms of the Repurchase Agreement, we agreed to pay each Series E Investor $300 per share of Series E Preferred Stock, or approximately $656,000, in consideration for the right to repurchase the Series E Investor’s Series E Preferred Stock at a price per share of $1,000 (the “Repurchase Price”), which was the original price per share paid by the Series E Investors for their Series E Preferred Stock in February 2015. We recognized the $656,000 payment as a deemed dividend paid to the Series E investors.

Immediately following the closing of our Series F public offering discussed below, we paid $2.2 million to the Series E Investors to repurchase all of the outstanding Series E Preferred Stock, in accordance with the terms of the Repurchase Agreement. Since almost none of the Series E Preferred Stock had converted by the time we repurchased the Series E Preferred Stock, the original $890,000 beneficial conversion feature that we recognized as a deemed dividend in 2015 was reversed as a return of capital from the Series E Preferred stockholders to the common stockholders.

Series F Convertible Preferred Stock and Warrants Financing

On March 24, 2016 (the “Series F Closing”), we closed an underwritten public offering (the “Series F Offering”) and issued 8,000 immediately separable units of securities to investors, with each unit consisting of: (i) one share of Series F convertible preferred stock (“Series F Preferred Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $3.87, which was 75% of the consolidated closing bid price of our common stock on The NASDAQ Capital Market on March 18, 2016, the date we executed the underwriting agreement (“UA date”); and (ii) 258.397875 warrants, each to purchase one share of our common stock at an exercise price per share equal to $5.17 (“Series F Warrants”), which was 100% of the consolidated closing bid price of our common stock on The NASDAQ Capital Market on the UA date. The Series F Preferred Stock, the Series F Warrants, and the shares of common stock underlying the Series F Preferred Stock and Series F Warrants were registered on Form S-1, which was declared effective by the SEC on March 18, 2016. The Series F Preferred Stock was immediately convertible and the Series F Warrants were immediately exercisable for shares of common stock and have a term of five years. The Series F Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. In total, there were 2,067,183 shares of common stock issuable upon conversion of the Series F Preferred Stock and up to 2,067,183 shares of common stock issuable upon exercise of the Series F Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds received by us of $8.0 million. Total offering-related costs paid through December 31, 2016 were $1.1 million, resulting in net proceeds recognized of $6.9 million. Given that the effective conversion price of the Series F Preferred Stock was below the closing market price of our common stock at the time of the Series F Closing, we recognized a beneficial conversion feature in the amount of $1.9 million. Since the Series F Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings at closing. Also, from the time of the Series F Closing through June 30, 2017, 7,908 shares of the Series F Preferred Stock have converted into 2,043,445 shares of common stock, leaving 92 shares of Series F Preferred Stock (representing 23,738 shares of common stock) unconverted.

The Series F Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to distributions upon our dissolution, liquidation or winding-up. Until the volume weighted average price of our common stock on NASDAQ exceeds 200% of the conversion price of the Series F Preferred Stock for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, the Series F Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to certain limitations. Also, the Company can force holders of Series F Preferred Stock to convert into our common stock if the volume-weighted average price of our common stock exceeds 200% of the Series F Preferred Stock conversion price for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, subject to certain other conditions. The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).

The Series F Warrants have a 5-year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series F Warrants. The Series F Warrants are not subject to price based anti-dilution protection. The Series F Warrants are listed on The NASDAQ Capital Market under the trading symbol “CBMXW.”

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Depending on the circumstances, upon a change in control constituting a “Fundamental Transaction” (as defined in the Series F Warrants), the holders of Series F Preferred Stock may be entitled to a 30% premium and the holders of Series F Warrants may have the right to require either that the Company purchase the Series F Warrants for an amount in cash that is determined in accordance with a formula set forth in the Series F Warrants or that the successor assumes and replaces the Series F Warrants with substantially equivalent warrants of the successor.

Common Stock Purchase Warrants Repurchase Agreement

On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings. Pursuant to the terms of the Warrants Repurchase Agreement, we have agreed to repurchase such Warrants from each Holder upon execution of a “Fundamental Transaction” (as defined in such Warrants) at various negotiated prices per Warrant share as set forth in the Warrants Repurchase Agreement. The Warrants Repurchase Agreement obligates us to repurchase half of such Warrants upon the announcement of a Fundamental Transaction. On July 31, 2017, we announced that we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Invitae Corporation (“Invitae”) and Coronado Merger Sub, Inc., a wholly owned subsidiary of Invitae (“Merger Sub”), pursuant to which Invitae plans to acquire us in an all-stock transaction in which Merger Sub will merge with and into us (the “Merger”). The Merger is considered a Fundamental Transaction under the Warrants Repurchase Agreement and, as a result of entering into and announcing the Merger Agreement, and pursuant to the terms of the Warrants Repurchase Agreement, we repurchased one half of such outstanding Warrants on August 3, 2017, for approximately $230,000 of cash consideration. Under the terms of the Warrants Repurchase Agreement, we will be obligated to repurchase the remaining half of such Warrants within three business days of any closing of the Merger. In addition, upon any closing of the Merger, all Securities Purchase Agreements and Registration Rights Agreements associated with the original issuances of such Warrants will be terminated and the various restrictions set forth therein will no longer be of any force or effect. In connection with entering into the Warrants Repurchase Agreement, we were granted certain consents and waivers relating to the Merger. If the Merger is consummated, we will be obligated to repurchase the remaining outstanding Warrants for approximately $230,000 which will be due within three business days of closing the Merger. In the event that we do not close the Merger or any other Fundamental Transaction, for whatever reason, then the remaining half of such Warrants will remain issued and outstanding. See Note 7 below.

Warrants

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
	June 30,		December 31,		Exercise
	2017		2016		Price		Expiration
Equity-classified warrants:
March 2016		2,067,076		2,067,176	$	5.17		March 2021
April 2015		100,847		100,847	$	16.50		August 2020
April 2015		1,831		1,831	$	32.51		August 2020
February 2015		46,676		46,676	$	16.50		August 2020
June 2014		1,690		1,690	$	30.90		April 2018
December 2013		388,365		388,365	$	46.80		December 2018
June 2013		32,788		32,788	$	29.55		June 2019
May 2013		32,788		32,788	$	29.55		May 2019
March 2013		18,334		18,334	$	29.55		March 2019
October 2012		11,252		11,252	$	29.55		September 2018
Total		2,701,647		2,701,747

The number of warrants set forth in the table above are as of June 30, 2017 and December 31, 2016 and do not reflect the repurchase of half of the Warrants we completed on August 3, 2017.

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

6. COMMITMENTS AND CONTINGENCIES

Executive Severance

We provide certain severance benefits such that if any of our executive officers is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (as amended, the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company. Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary (one times annual base salary for the Chief Executive Officer); (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time. Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code. The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors. In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements. The Severance Plan automatically renews annually unless terminated upon 12 months prior written notice. We expect that our Chief Executive Officer and Chief Financial Officer will receive benefits under the Severance Plan as a result of any consummation of the Merger.

Also, our Board of Directors and Compensation Committee have adopted a Transaction Bonus Plan (the “Transaction Bonus Plan”), which provides for certain bonus payments to be made, upon any consummation of a qualifying change of control transaction such as the Merger, to certain participants as shall be determined from time to time by the Compensation Committee of our Board of Directors. The aggregate value of the bonuses payable under the Transaction Bonus Plan shall be the greater of (i) $1,000,000 or (ii) ten percent of the net proceeds received in connection with a qualifying change of control transaction such as the Merger, and the percentage of such bonus pool awarded to each eligible participant shall be determined from time to time by our Compensation Committee.

Litigation

In 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 and $50,000 for both of the three and six months ended June 30, 2017 and 2016, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.

From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

7. SUBSEQUENT EVENTS

On July 31, 2017, we entered into the Merger Agreement with Invitae, pursuant to which Invitae plans to acquire us through an all-stock Merger. The Merger is subject to certain closing conditions, as set forth in the Merger Agreement, including, among others, obtaining certain regulatory approvals, approval from our stockholders, Invitae’s registration of common stock to be used to acquire us, and at least 90% participation in a Series F Warrants exchange offer that will be conducted by Invitae in connection with the Merger.

The Merger Agreement contains certain termination rights for both us and Invitae, including, among others, if the Merger is not consummated on or before January 31, 2018 (unless due to the terminating party’s action or failure to act or SEC delay) or if the approval of our stockholders is not obtained. If the Merger Agreement is terminated by either us or Invitae as a result of a breach by the other party of any of such other party’s representations, warranties or covenants, or because the occurrence of a material adverse effect applicable to such party was the sole failed condition to closing, or if the Merger Agreement is terminated by Invitae as a result of the failure of our stockholders to approve the Merger Agreement or as a result of an adverse change in the recommendation of our board of directors, then the defaulting party will be obligated to reimburse the other party’s third party expenses up to a maximum of $400,000. The Merger Agreement further provides that, upon termination of the Merger Agreement under specified circumstances, including, among others, termination of the Merger Agreement as a result of an adverse change in the recommendation of our board of directors after receiving a bona fide alternative acquisition proposal or termination of the Merger Agreement as a result of our stockholders not approving the Merger Agreement following disclosure of a bona fide acquisition proposal after which we are sold within 12 months, we may be required to pay to Invitae a termination fee of up to $1.4 million.

The foregoing description of the Merger Agreement is not a complete description of all of the parties’ rights and obligations under the Merger Agreement and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to our Current Report on Form 8-K filed with the SEC on July 31, 2017.

As a result of entering into and announcing the Merger Agreement, and pursuant to the terms of the Warrants Repurchase Agreement, On August 3, 2017, we repurchased one-half of the outstanding Warrants for approximately $230,000 of cash consideration. The remaining half will be due within three business days of any closing of the Merger.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement

You should read the following discussion and analysis in conjunction with the consolidated financial statements and related notes thereto contained in Part I, Item 1 of this report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our businesses or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the U.S. Securities and Exchange Commission, or “SEC,” including our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017.

This report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included in this report, are forward-looking statements. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report. Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “would,” “could,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “seek,” “potential,” “more likely to,” “with a view to,” “our future success depends,” “continue,” “focus,” “ongoing,” or similar terms, variations of such terms or the negative of such terms, and include, but are not limited to, statements regarding projected results of operations, capital expenditures, earnings, management’s future strategic plans, development of new technologies and services, litigation, regulatory matters, market acceptance and performance of our services, the success and effectiveness of our technologies and services, our ability to retain and hire key personnel, the competitive nature of and anticipated growth in our markets, market size, market position of our services, marketing efforts and partnerships, liquidity and capital resources, our accounting estimates, and our assumptions and judgments. Such statements are based on management’s current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. These forward looking statements are not guarantees of future results and are subject to a number of risks, uncertainties and assumptions that are difficult to predict and that could cause actual results to differ materially and adversely from those described in the forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, the risk that holders of less than 90% of our Series F Warrants tender their securities or our stockholders fail to approve the Merger and the Merger Agreement is terminated due to these reasons; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the possibility that the proposed Merger is delayed; the inability to complete the Merger due to the failure to satisfy any of the conditions to completion of the Merger; the impact of the announcement or the completion of the Merger on the market price of our or Invitae’s common stock, or on our or Invitae’s relationships with employees, existing customers and suppliers or potential future customers and suppliers and on our or Invitae’s operating results and businesses generally; the ability of Invitae to successfully integrate our operations and employees; the ability to realize anticipated synergies and costs savings of the proposed Merger; the risk that if the Merger is terminated and we have to pay termination fees and transaction expenses, we may not have sufficient funds to make such payments; our ability to grow revenue and improve gross margin; delays in achieving cash flow-positive operating results; the risk that operating expenses are not reduced or increase; the risk that test volumes and reimbursements level off or decline; the risk that payors decide to not cover our tests or to reduce the amounts they are willing to pay for our tests; the risk that we will not be able to grow our business as quickly as we need to; our ability to successfully increase the volume of our existing tests, expand the number of tests offered by our laboratory, increase the number of customers and partners and improve reimbursement for our testing; market acceptance of chromosomal microarray analysis, or CMA, as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; changes in consumer demand; third-party reimbursement of CMA; our ability to attract and retain a qualified sales force and key technical personnel; our ability to successfully develop and introduce new technologies and services; rapid technological change in our markets; supply availability; our ability to bill and obtain reimbursement for highly specialized tests; the rate of growth of the in vitro fertilization, or IVF, diagnostic testing market; our ability to comply with regulations to which our business is subject, including changes in coding and reimbursement methods; legislative, regulatory and competitive developments in markets in which we and our subsidiaries operate; our limited market capitalization; our ability to obtain additional financing for working capital on acceptable terms and in a timely manner; future economic conditions; other circumstances affecting anticipated revenues and costs; and other factors as more fully disclosed in our discussion of risk factors in Item 1A of Part II of this report and in the “Risk Factors” described in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017. These forward-looking statements speak only as of the date of this report and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise required by law.

General

We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.

We also own a one-third minority interest in Leuchemix, Inc., a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

Overview of Recent Developments and Business Activities

For the three and six months ended June 30, 2017, our business activities were driven primarily by continued commercialization efforts for our suite of molecular diagnostic tests and expansion of our executive oversight and leadership. For the three and six months ended June 30, 2017, our operating activities included the recognition of $4.2 million and $8.0 million of total revenues, respectively, which increased by $1.1 million and $1.9 million, respectively, from the comparable 2016 periods. These increases were due primarily to increased testing volumes and improved pricing and reimbursement of our microarray diagnostic tests, particularly in the reproductive health testing market (defined as testing volumes from prenatal, miscarriage analysis and pre-implantation genetic screening, or PGS diagnostic tests). Revenues from our reproductive health testing services increased by 44% and 38% during the three and six months ended June 30, 2017, respectively, compared to the comparable periods in 2016. Total diagnostic testing revenues during the three and six months ended June 30, 2017 increased by 38% and 33%, respectively, over the comparable periods in 2016. For the three and six months ended June 30, 2017, our net loss decreased by $865,000 and $1.8 million, respectively, compared to the comparable 2016 periods, due to increased revenues, improved gross margins and relatively flat operating expenses for all periods presented.

In January 2017, we appointed Dr. James W. Wheless to our Scientific Advisory Board. Dr. Wheless is a Diplomat of the American Board of Pediatrics and the American Board of Psychiatry and Neurology with special qualifications in child neurology, clinical neurophysiology and epilepsy. He is a fellow of the American Academy of Pediatrics and the American Academy of Neurology.

In February 2017, we appointed Dirk van den Boom, Ph.D., to our Board of Directors. Dr. van den Boom most recently served as President, Chief Executive Officer and Director of publicly traded molecular diagnostics company Sequenom, Inc., prior to that company’s acquisition by Laboratory Corporation of America in September 2016. Dr. van den Boom has co-authored more than 95 articles published in peer-reviewed journals and is inventor on more than 80 patents and patent applications.

In July 2017, we entered into the Merger Agreement with Invitae, pursuant to which Invitae plans to acquire us through an all-stock Merger. The Merger is subject to certain closing conditions, as set forth in the Merger Agreement, including, among others, obtaining certain regulatory approvals, approval from our stockholders, Invitae’s registration of common stock to be used to acquire us, and at least 90% participation in a Series F Warrants exchange offer that will be conducted by Invitae in connection with the Merger. We expect to incur significant expenses in connection with the Merger. While we have assumed that a certain level of expenses will be incurred, there are many factors that could affect the total amount or the timing of the Merger expenses, and many of the expenses that will be incurred are, by their nature, difficult to estimate. The ultimate amount and timing of such charges are uncertain at the present time.

As a result of entering into and announcing the Merger Agreement, and pursuant to the terms of the Warrants Repurchase Agreement, on August 3, 2017, we repurchased one half of the outstanding Warrants for approximately $230,000 of cash consideration. The remaining half will be due within three business days of any closing of the Merger.

Critical Accounting Estimates

Our unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Preparation of these statements requires management to make judgments and estimates. Some accounting policies have a significant impact on amounts reported in these financial statements. A summary of significant accounting policies and a description of accounting policies that are considered critical may be found in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017, in the Notes to the Consolidated Financial Statements and the Critical Accounting Estimates sections. In addition, refer to Note 2 to the consolidated interim financial statements included in Part I, Item 1 of this report.

Comparison of the Results of Operations for the Three and Six Months Ended June 30, 2017 and 2016

Revenues and Cost of Services (dollars in thousands):

	Three Months Ended												Six Months Ended
	June 30,						Change						June 30,						Change
	2017			2016			$			%			2017			2016			$			%

Diagnostic services revenues	$	4,214		$	3,049		$	1,165			38%		$	7,972		$	5,979		$	1,993			33%
Royalty revenues		27			58			(31	)		(53%	)		56			100			(44	)		(44%	)
Cost of services		(1,632	)		(1,432	)		(200	)		(14%	)		(3,140	)		(2,851	)		(289	)		(10%	)

Diagnostic Services Revenues. Diagnostic services revenues are generated from providing DNA-based genomic testing services primarily in the areas of PGS, miscarriage analysis, prenatal diagnostics (collectively referred to as “reproductive health” testing) and postnatal development disorders in children. The key drivers and metrics relating to the change in diagnostic services revenues were as follows:

	Three Months Ended								Six Months Ended
	June 30,				Change				June 30,				Change
	2017		2016		#		%		2017		2016		#		%

Total billable tests		3,087		2,780		307		11%		6,025		5,428		597		11%
Total reproductive health microarray tests (1)		1,748		1,403		345		25%		3,390		2,829		561		20%
Reproductive health percentage of total billable tests		56.6%		50.5%						56.3%		52.1%

Revenue per test - total billable tests	$	1,365	$	1,097	$	268		24%	$	1,323	$	1,102	$	221		20%
Revenue per test - total reproductive health microarray tests (1)	$	1,795	$	1,555	$	240		15%	$	1,768	$	1,536	$	232		15%

(1)	includes PGS, PGD, prenatal and miscarriage analysis microarray tests

For the three months ended June 30, 2017, total billable tests and total diagnostic services revenues increased by 11% and 38%, respectively, compared to the three months ended June 30, 2016. For the six months ended June 30, 2017, total billable tests and total diagnostic services revenues increased by 11% and 33%, respectively, compared to the six months ended June 30, 2016. Driving the increase in total billable tests and diagnostic services revenues for all periods presented were the increases in reproductive health testing volumes, which increased by 25% and 20% for the three and six months ended June 30, 2017 compared to the comparable 2016 periods, respectively. We believe this reflects the commercialization strategies and focus of our sales force, which have emphasized reproductive health microarray diagnostics testing over traditional genomics testing. In addition, improved reimbursement from third-party payors for our microarray tests drove higher revenues per test in our reproductive health segment, thereby resulting in a higher percentage increase in total diagnostic services revenues compared to the percentage increase in diagnostic testing volumes.

Diagnostic services revenues are recognized based on: i) contractual rates billed to our customers and certain third party payors; and ii) amounts that we expect to collect from non-contracted third-party payors, which include adjustments for changes in estimates of contractual allowances as well as from receiving cash payments in excess of amounts previously recognized. Because approximately 72% of our diagnostic revenues in 2017 resulted from billings to third-party payors, most of which are non-contracted, it is likely that we will be required to make adjustments to these accounting estimates in the future, which may positively or adversely affect our revenues and results of operations.

Royalties. In 2010, we entered into an exclusive licensing agreement with CustomArray, Inc. (“CA”), a private company located in Washington State, to license from us certain of our patents and intellectual property developed as part of our prior microarray manufacturing business. This agreement requires CA to pay us royalties as a percentage of their gross revenues, with a minimum floor of not less than $25,000 per quarter. The changes in royalty revenues reported reflect changes in CA’s revenues. It is uncertain whether in future periods, CA’s revenues will increase or continue at the minimum contractual amounts.

Cost of Services. Cost of services relating to our diagnostic tests performed include direct materials such as microarray slides, reagents and related laboratory materials, direct laboratory labor (wages and benefits), allocation of administrative overhead and stock-compensation expenses. Increases in cost of services for all periods presented were due primarily to increased diagnostic testing volumes previously discussed. Non-cash stock compensation expenses were not significant for the periods presented.

Operating Expenses (dollars in thousands):

	Three Months Ended										Six Months Ended
	June 30,				Change						June 30,				Change
	2017		2016		$			%			2017		2016		$			%

Research and development	$	85	$	149	$	(64	)		(43%	)	$	170	$	292	$	(122	)		(42%	)
Sales and marketing		1,016		1,141		(125	)		(11%	)		2,038		2,477		(439	)		(18%	)
General and administrative		1,855		1,586		269			17%			3,519		3,112		407			13%

Research and Development. These expenses include labor (wages and benefits), non-cash stock compensation expenses and laboratory supply costs associated with investigating and validating new tests and technology platforms, costs to maintain and improve our existing suite of diagnostic tests offered and process improvement projects. Prior to launching a new test or technology, or modifying an existing test, appropriate clinical trials and extensive laboratory validations, consistent with the various regulations that govern our industry, must be performed. These costs are classified as research and development for all periods presented. For the three and six months ended June 30, 2017, research and development expenses decreased from the comparable 2016 periods due primarily to greater efforts during 2016 in launching a next generation sequencing platform for our PGS testing services coupled with validating new microarray testing platforms for our miscarriage analysis tests. These efforts were not repeated during the three and six month periods ended June 30, 2017. Non-cash stock compensation expenses were not significant for the periods presented.

Sales and Marketing. These expenses include salaries and wages associated with our sales force and marketing resources, sales commissions and other expenses associated with promotional and advertising efforts as well as non-cash stock compensation expenses. For the three and six months ended June 30, 2017, sales and marketing expenses decreased from the comparable 2016 periods due primarily to reduced headcount in sales representatives coupled with newer sales representatives earning lower base salaries compared to the prior year mix of sales representatives, coupled with reduced travel and entertainment costs from fewer sales headcount in the 2017 periods compared to the 2016 periods presented. Non-cash stock compensation expenses were not significant for the periods presented.

General and Administrative. These expenses include compensation and benefit costs of our administrative staff, client billing and collections, information technology, executive management, human resources and accounting personnel, as well as facilities-related costs, insurance, legal, audit and other professional services. For the three and six months ended June 30, 2017, general and administrative expenses increased from the comparable 2016 periods due primarily to increased legal and bad debt expenses. Also included in general and administrative expenses are non-cash stock-based compensation expenses, which were $128,000, $294,000, $169,000 and $341,000 for the three and six months ended June 30, 2017 and 2016, respectively. Changes to stock-based compensation expenses are driven by timing of when newer option awards are granted compared to when older awards become fully vested or expire due to forfeitures, as well as by the differences in valuations attributed to individual awards at the time they are granted. See Note 2 to our consolidated interim financial statements included in Part I, Item 1 of this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

Inflation

Inflation has not had a significant impact on our business, results of operations or financial condition.

Liquidity and Capital Resources

At June 30, 2017, cash and cash equivalents totaled $3.0 million, compared to $3.7 million at December 31, 2016. Cash is held primarily in general checking accounts as well as in money market mutual funds backed by U.S. government securities. When held, short-term investments typically are comprised primarily of certificates of deposits issued by U.S. financial institutions. Working capital was $5.6 million and $6.1 million at June 30, 2017 and December 31, 2016, respectively. The primary reason for the decrease in working capital was due to lower overall cash balances at June 30, 2017 compared to December 31, 2016, driven by operating, investing and financing activities described below.

The net change in cash and cash equivalents for the periods presented was comprised of the following (in thousands):

	Six Months Ended
	June 30,
	2017			2016			Change
Net cash provided by (used in):
Operating activities	$	(607	)	$	(2,544	)	$	1,937
Investing activities		996			2,603			(1,607	)
Financing activities		(94	)		4,015			(4,109	)
Increase in cash and cash equivalents	$	295		$	4,074		$	(3,779	)

Operating Activities. Higher cash inflows from improved cash collections coupled with slightly lower overall operating expenses during the six months ended June 30, 2017 resulted in lower cash used in operating activities compared to the six months ended June 30, 2016.

Investing Activities. The decrease in net cash flows from investing activities was due to reduced net sales of available-for-sale short-term investments made during the six months ended June 30, 2017 compared to the comparable period in 2016.

Financing Activities. The decrease in net cash flows from financing activities was due primarily to the $6.9 million of net proceeds received from the March 2016 Series F Financing, partially offset by the $2.8 million repurchase of Series E preferred stock and dividends paid to the Series E investors commensurate with the 2016 Series F Financing, compared to no sales or repurchases of CombiMatrix securities in 2017.

Future Liquidity. We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new services and continue to develop commercial technologies and services. We believe that our cash and cash equivalents as of June 30, 2017, which totaled $3.0 million, will be sufficient to meet our expected cash requirements for current operations through and beyond the fourth quarter of 2017, when we anticipate achieving cash flow break-even status. If the Merger is terminated, however, and we have to pay termination fees and transaction expenses, we may not have sufficient funds to make such payments. In order for us to continue as a going concern beyond this point and to ultimately achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and on terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. Also, in order to issue securities at a price below the exercise prices of our outstanding warrants issued in connection with our past preferred stock private placement financings, we must obtain the affirmative consent of holders of at least 67% of each series of such outstanding warrants. If we are unable to obtain the consent of these holders in connection with future financings, we may be unable to raise additional capital on acceptable terms, or at all. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could compromise our future strategic initiatives and business plans.

Capital Requirements. We may also encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated. As a result, we may be required to seek additional funding through equity, debt or other external financing, and there can be no assurance that additional funding will be available on favorable terms, in a timely fashion or at all. At this time, we have no significant commitments for capital expenditures in 2017 or beyond. However, our long-term capital requirements could be substantial and the adequacy of available funds will depend upon many factors, including:

	●	the costs of commercialization activities, including sales and marketing costs and capital equipment;

	●	competing technological developments;

	●	the creation and formation of strategic partnerships;

	●	variability in third-party reimbursement for our diagnostic tests;

	●	the costs associated with leasing and improving our Irvine, California facility; and

	●	other factors that may not be within our control.

Off-Balance Sheet Arrangements

As of June 30, 2017, we did not have any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC. We have entered into an operating lease for our laboratory space and corporate offices, totaling approximately 12,200 square feet, expiring in early 2020. We have no significant commitments for capital expenditures for the remainder of 2017 or beyond. We currently have eight active capital leases totaling $236,000 for certain laboratory and IT-related equipment, with lease payments continuing through February 2021.

Recent Accounting Pronouncements

See Note 2 to the consolidated interim financial statements included in Part I, Item 1 of this report for a discussion on recent accounting pronouncements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and our principal financial officer concluded that as of June 30, 2017, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods prescribed by the SEC and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our last fiscal quarter (the quarter ended June 30, 2017) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we are involved in other litigation arising in the normal course of business. Management believes that resolution of these other matters will not result in any payment that, in the aggregate, would be material to our financial position or results of operations.

Item 1A. RISK FACTORS

The following risk factors include any and all material changes to, and should be read in conjunction with, the risk factors contained in Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 3, 2017.

The Merger is subject to a number of conditions beyond our control. Failure to complete the Merger within the expected time frame or at all could adversely affect our stock price and our future business and financial results.

The Merger is subject to a number of conditions beyond our control that may prevent, delay or otherwise materially adversely affect its completion, including, without limitation, obtaining certain regulatory approvals, the absence of a material adverse effect upon either party, approval from our stockholders, Invitae’s registration of common stock to be used to acquire us, and at least 90% participation in a Series F Warrants exchange offer that will be conducted by Invitae in connection with the Merger. We cannot predict whether and when these conditions will be satisfied. Any delay in completing the Merger could cause the combined company not to realize some or all of the synergies expected to be achieved. We will also incur certain transaction costs whether or not the Merger is completed. In addition, if the Merger is terminated due to certain circumstances and we have to pay termination fees and transaction expenses, we may not have sufficient funds to make such payments. Any failure to complete the Merger could have a material adverse effect on our stock price and our future business and financial results.

Uncertainty about the Merger and diversion of management could harm us or the combined company, whether or not the Merger is completed.

The announcement of the Merger or the pendency of the proposed transaction may disrupt our current plans and operations and could result in current and prospective employees, customers, payers, partners and suppliers experiencing uncertainty about their future with us or the combined company. These uncertainties may impair our ability to retain, recruit or motivate key personnel or to increase our customers, payers and partners. Completion of the Merger will also require a significant amount of time and attention from our management. The diversion of management’s attention away from ongoing operations could adversely affect our business relationships. If the Merger is not consummated during the fourth quarter of 2017, as currently anticipated, the adverse effects of these uncertainties and the diversion of management’s attention could be exacerbated by the delay. Even if the Merger is consummated, integration of operations will require substantial time after consummation of the Merger, and the combined company may lose management personnel and other key employees and be unable to attract and retain such personnel and employees.

The anticipated benefits of the Merger may not be realized fully or at all or may take longer to realize than expected.

The Merger involves the integration of two companies that have previously operated independently. Prior to announcement, we did not conduct any integration planning for the two companies, and our ability to do so prior to consummation of the Merger is substantially limited by applicable law. After the Merger, the two companies will devote significant management attention and resources to integrating the two companies. Delays in this process could adversely affect the combined company’s business, financial results, financial condition and stock price. Even if we are able to integrate our business operations successfully, there can be no assurance that this integration will result in the realization of the full benefits of synergies, cost savings, innovation and operational efficiencies that we currently expect from this integration or that these benefits will be achieved within the anticipated time frame.

The combined company may also be unable to use our current net operating loss carryforwards to offset future taxable income for U.S. federal income tax purposes. Changes in services, changes in sources of revenue, and branding or rebranding initiatives may involve substantial costs and may not be favorably received by customers, resulting in an adverse impact on the combined company’s financial results, financial condition and stock price.

Neither the Merger exchange ratio nor the amount that will be offered to Series F Warrant holders in the Series F Warrants exchange offer is adjustable based on the market price of Invitae common stock so the Merger consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed.

The Merger Agreement establishes the exchange ratio for our common stock and preferred stock and establishes the amount that will be offered to Series F Warrant holders in the Series F Warrants exchange offer, and any changes in the market price of Invitae common stock before the completion of the Merger will not affect the number of shares our security holders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the Merger the market price of Invitae common stock declines from the market price on the date of the Merger Agreement, then our security holders could receive Merger consideration with substantially lower value. Similarly, if before the completion of the Merger the market price of Invitae common stock increases from the market price on the date of the Merger Agreement, then our security holders could receive Merger consideration with substantially more value for their shares of our capital stock than the parties had negotiated for in the establishment of the exchange ratio. Because the exchange ratio does not adjust as a result of changes in the value of Invitae common stock, for each one percentage point that the market value of Invitae common stock rises or declines, there is a corresponding one percentage point rise or decline, respectively, in the value of the total Merger consideration issued to our security holders.

The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.

In general, either we or Invitae can refuse to complete the Merger if there is a material adverse change affecting the other party between the date of the Merger Agreement and the closing. However, certain types of changes do not permit either party to refuse to complete the Merger, even if such change could be said to have a material adverse effect on us or Invitae, including:

	●	conditions generally affecting the industries in which we and Invitae operate or the United States or global economy or capital markets as a whole;

	●	any natural disaster or any acts of terrorism, sabotage, military action or war or any escalation of worsening thereof;

	●	changes in regulatory, legislative or political conditions in the United States or any other country or region in the world;

	●	changes in conditions in the financial markets, credit markets or capital markets in the United States or any other country or region in the world;

	●	any effect resulting from the execution, delivery, announcement or performance of the obligations under the Merger Agreement or the announcement, pendency or anticipated consummation of the Merger;

	●	any failure by us or Invitae to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending on or after the date of the Merger Agreement;

	●	any changes in GAAP or applicable legal requirements after the date of the Merger Agreement;

	●	any rejection by a governmental body of a registration or filing by us relating to certain intellectual property rights; or

	●	any change in our cash position which results from operations in the ordinary course of business.

If adverse changes occur and we and Invitae still complete the Merger, the combined organization stock price may suffer. This in turn may reduce the value of the Merger consideration to our security holders.

We may not be able to meet our cash requirements beyond August of 2018 without obtaining additional capital from external sources and our current outstanding private placement warrants may prevent us from issuing new securities. If we are unable to raise additional capital through future financings or from external sources, we may not be able to continue as a going concern.

As of June 30, 2017, we had $3.0 million in cash and cash equivalents, which we anticipate will meet our cash requirements through and beyond the fourth quarter of 2017. However, in order for us to continue as a going concern beyond that point, we will have to increase revenue and cash reimbursement, continue to control operating expenses and may be required to obtain capital from external sources. Our ability to continue as a going concern is dependent upon our ability to further implement our business plan, generate sufficient revenues and cash reimbursement and to control operating expenses, of which there can be no assurance.

In order to issue securities at a price below the exercise prices of our outstanding warrants issued in connection with our past preferred stock private placement financings, we must obtain the affirmative consent of holders of at least 67% of each series of such outstanding warrants. If we are unable to obtain the consent of these holders in connection with future financings, we may be unable to raise additional capital on acceptable terms, or at all. If external financing sources are not available in a timely manner or at all, or are inadequate to fund our operations, we could experience reduced revenues and cash flows from the sales of our diagnostic services and our ability to launch, market and sell additional services necessary to grow and sustain our operations could be jeopardized.

Our stock price could decline because of the potentially dilutive effect of future financings and from the exercises of certain common stock warrants.

As of June 30, 2017, we had approximately 2.9 million shares of common stock issued and outstanding. Assuming exercise in full of all options, warrants and convertible securities outstanding as of June 30, 2017, approximately 5.8 million shares of our common stock would be outstanding. Any additional equity or convertible debt financings in the future could result in further dilution to our stockholders.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

An index of exhibits is found on page 28 of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COMBIMATRIX CORPORATION

	By:	/s/ MARK MCDONOUGH
		Mark McDonough
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ SCOTT R. BURELL
		Scott R. Burell
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Date: August 11, 2017

EXHIBIT INDEX

Exhibit Number		Description

2.1		Agreement and Plan of Merger and Reorganization by and among the Company, Invitae and Merger Sub, dated as of July 31, 2017. Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (SEC File No. 001-33523) filed with the SEC on July 31, 2017.
3.1		Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (SEC File No. 333-139679) filed with the SEC on December 26, 2006.
3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1A to the Company’s Quarterly Report on Form 10-Q (File No. 001-33523) filed with the SEC on August 14, 2008.
3.3		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on December 4, 2012.
3.4		Certificate of Designation of Preferences, Rights and Limitations of Series A 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on October 1, 2012.
3.5		Certificate of Designation of Preferences, Rights and Limitations of Series B 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on March 20, 2013.
3.6		Certificate of Designation of Preferences, Rights and Limitations of Series C 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on May 6, 2013.
3.7		Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on December 23, 2013.
3.8		Certificate of Designation of Preferences, Rights and Limitations of Series E 6% Convertible Preferred Stock. Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on February 13, 2015.
3.9		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on April 29, 2015.
3.10		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on January 29, 2016.
3.11		Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on March 24, 2016.
3.12		Second Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33523) filed with the SEC on March 18, 2010.
10.1		Amended and Restated 2017 Executive Performance Bonus Plan. Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-33523) filed with the SEC on June 19, 2017.
31.1		Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)
31.2		Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)
32.1		Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2		Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.0		The following materials from CombiMatrix Corporation’s Quarterly Report on Form 10-Q for the quarter and six month periods ended June 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016; (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016; (iii) Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2017 and 2016; (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and 2016; and (v) Notes to Consolidated Financial Statements.(*)

(*)	Included herewith.

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McDonough, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

		c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

		d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 11, 2017	/s/ MARK MCDONOUGH
	Mark McDonough Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Scott R. Burell, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

		c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

		d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting

Date: August 11, 2017	/s/ SCOTT R. BURELL
	Scott R. Burell Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), I, Mark McDonough, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:

	/s/ MARK MCDONOUGH
	Mark McDonough Chief Executive Officer (Principal Executive Officer) August 11, 2017

This certification accompanies this report and is being furnished pursuant to Item 601(b)(32) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This certification shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, or incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference into such a filing.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), I, Scott R. Burell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:

	/s/ SCOTT R. BURELL
	Scott R. Burell Chief Financial Officer
	(Principal Financial and Accounting Officer) August 11, 2017

EX-101.INS 6 cbmx-20170630.xml XBRL INSTANCE FILE 0001383183 2017-01-01 2017-06-30 0001383183 2016-12-31 0001383183 2017-06-30 0001383183 us-gaap:SeriesFPreferredStockMember 2016-12-31 0001383183 us-gaap:SeriesFPreferredStockMember 2017-06-30 0001383183 2016-01-01 2016-06-30 0001383183 us-gaap:MaximumMember 2017-06-30 0001383183 us-gaap:MinimumMember 2017-06-30 0001383183 us-gaap:SalesRevenueNetMember CBMX:NoSingleCustomerMember 2017-01-01 2017-06-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceCarrierAMember 2017-01-01 2017-06-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceCarrierBMember 2016-01-01 2016-12-31 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceCarrierAMember 2017-06-30 0001383183 us-gaap:AccountsReceivableMember CBMX:CommercialInsuranceCarrieBMember 2016-12-31 0001383183 us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001383183 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001383183 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001383183 CBMX:CommonStockWarrantsMember 2017-01-01 2017-06-30 0001383183 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001383183 CBMX:CommonStockWarrantsMember 2016-01-01 2016-06-30 0001383183 CBMX:CashAndMoneyMarketSecuritiesMember 2017-06-30 0001383183 us-gaap:CommercialPaperMember 2017-06-30 0001383183 us-gaap:CertificatesOfDepositMember 2017-06-30 0001383183 CBMX:CashAndMoneyMarketSecuritiesMember 2016-12-31 0001383183 us-gaap:CommercialPaperMember 2016-12-31 0001383183 us-gaap:CertificatesOfDepositMember 2016-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0001383183 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001383183 CBMX:SeriesAWarrantsMember us-gaap:MaximumMember 2017-06-30 0001383183 CBMX:SeriesBWarrantsMember 2017-06-30 0001383183 CBMX:SeriesCWarrantsMember 2017-06-30 0001383183 CBMX:SeriesESixPercentConvertiblePreferredStockMember 2016-02-03 2016-02-04 0001383183 CBMX:SeriesESixPercentConvertiblePreferredStockMember 2016-02-04 0001383183 CBMX:SeriesEInvestorsMember 2016-02-03 2016-02-04 0001383183 CBMX:SeriesFOfferingMember 2016-03-23 2016-03-24 0001383183 CBMX:SeriesFOfferingMember 2016-03-18 0001383183 CBMX:SeriesFConvertiblePreferredStockAndWarrantsFinancingMember 2016-03-18 0001383183 us-gaap:SeriesFPreferredStockMember 2016-03-24 0001383183 us-gaap:SeriesFPreferredStockMember us-gaap:MaximumMember 2016-03-24 0001383183 us-gaap:SeriesFPreferredStockMember 2016-03-23 2016-03-24 0001383183 CBMX:SeriesFOfferingMember 2016-12-31 0001383183 CBMX:SeriesFOfferingMember 2016-01-01 2016-12-31 0001383183 CBMX:SeriesFOfferingMember us-gaap:SeriesFPreferredStockMember 2017-06-30 0001383183 CBMX:SeriesFOfferingMember us-gaap:CommonStockMember 2017-06-30 0001383183 CBMX:MarchTwoThousandSixteenMember 2017-06-30 0001383183 CBMX:MarchTwoThousandSixteenMember 2016-12-31 0001383183 CBMX:AprilTwoThousandFifteenMember 2017-06-30 0001383183 CBMX:AprilTwoThousandFifteenMember 2016-12-31 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2017-06-30 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2016-12-31 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2017-06-30 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2016-12-31 0001383183 CBMX:JuneTwoThousandFourteenMember 2017-06-30 0001383183 CBMX:JuneTwoThousandFourteenMember 2016-12-31 0001383183 CBMX:DecemberTwoThousandThirteenMember 2017-06-30 0001383183 CBMX:DecemberTwoThousandThirteenMember 2016-12-31 0001383183 CBMX:JuneTwoThousandThirteenMember 2017-06-30 0001383183 CBMX:JuneTwoThousandThirteenMember 2016-12-31 0001383183 CBMX:MayTwoThousandThirteenMember 2017-06-30 0001383183 CBMX:MayTwoThousandThirteenMember 2016-12-31 0001383183 CBMX:MarchTwoThousandThirteenMember 2017-06-30 0001383183 CBMX:MarchTwoThousandThirteenMember 2016-12-31 0001383183 CBMX:OctoberTwoThousandTwelveMember 2017-06-30 0001383183 CBMX:OctoberTwoThousandTwelveMember 2016-12-31 0001383183 CBMX:MarchTwoThousandSixteenMember 2017-01-01 2017-06-30 0001383183 CBMX:AprilTwoThousandFifteenMember 2017-01-01 2017-06-30 0001383183 CBMX:AprilTwoThousandFifteenOneMember 2017-01-01 2017-06-30 0001383183 CBMX:FebruaryTwoThousandFifteenMember 2017-01-01 2017-06-30 0001383183 CBMX:JuneTwoThousandFourteenMember 2017-01-01 2017-06-30 0001383183 CBMX:DecemberTwoThousandThirteenMember 2017-01-01 2017-06-30 0001383183 CBMX:JuneTwoThousandThirteenMember 2017-01-01 2017-06-30 0001383183 CBMX:MayTwoThousandThirteenMember 2017-01-01 2017-06-30 0001383183 CBMX:MarchTwoThousandThirteenMember 2017-01-01 2017-06-30 0001383183 CBMX:OctoberTwoThousandTwelveMember 2017-01-01 2017-06-30 0001383183 CBMX:TransactionBonusPlanMember 2017-06-30 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2002-12-31 0001383183 CBMX:LitigationMember CBMX:SettlementAgreementMember 2002-01-01 2002-12-31 0001383183 CBMX:SeriesFConvertiblePreferredStockAndWarrantsFinancingMember 2016-03-23 2016-03-24 0001383183 CBMX:WarrantRepurchaseAgreementsMember 2016-07-10 2016-07-11 0001383183 CBMX:SeriesEWarrantsMember 2017-06-30 0001383183 2016-06-30 0001383183 CBMX:SeriesFWarrantsMember 2017-01-01 2017-06-30 0001383183 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001383183 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0001383183 CBMX:SeriesFPreferredStockConvertibleintoCommonStockMember 2017-01-01 2017-06-30 0001383183 CBMX:SeriesFPreferredStockConvertibleintoCommonStockMember 2016-01-01 2016-06-30 0001383183 CBMX:SeriesFOfferingMember 2016-03-17 2016-03-18 0001383183 us-gaap:SeriesFPreferredStockMember 2017-01-01 2017-06-30 0001383183 us-gaap:SeriesFPreferredStockMember 2017-06-30 0001383183 2015-12-31 0001383183 CBMX:SeriesFOfferingMember us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001383183 2017-08-07 0001383183 2016-04-01 2016-06-30 0001383183 2017-04-01 2017-06-30 0001383183 us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001383183 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001383183 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001383183 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001383183 CBMX:CommonStockWarrantsMember 2017-04-01 2017-06-30 0001383183 CBMX:SeriesFPreferredStockConvertibleintoCommonStockMember 2017-04-01 2017-06-30 0001383183 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001383183 us-gaap:RestrictedStockUnitsRSUMember 2016-04-01 2016-06-30 0001383183 CBMX:CommonStockWarrantsMember 2016-04-01 2016-06-30 0001383183 CBMX:SeriesFPreferredStockConvertibleintoCommonStockMember 2016-04-01 2016-06-30 0001383183 us-gaap:SubsequentEventMember CBMX:MergerAgreementMember 2017-06-30 0001383183 us-gaap:SubsequentEventMember CBMX:MergerAgreementMember CBMX:SeriesFWarrantsMember 2017-07-31 0001383183 CBMX:WarrantRepurchaseAgreementsMember us-gaap:SubsequentEventMember 2017-08-02 2017-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CBMX:Segment CombiMatrix Corp 10-Q 2017-06-30 false --12-31 Smaller Reporting Company Q2 2918726

2727000

3022000

1000000

232000

227000

5000000

8000

969

0.001

50000000

2000

-888000

-2724000

-370000

-1235000

2727000

3022000

4727000

653000

6. COMMITMENTS AND CONTINGENCIES   Executive Severance   We provide certain severance benefits such that if any of our executive officers is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (as amended, the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company. Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary (one times annual base salary for the Chief Executive Officer); (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time. Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code. The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors. In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements. The Severance Plan automatically renews annually unless terminated upon 12 months prior written notice. We expect that our Chief Executive Officer and Chief Financial Officer will receive benefits under the Severance Plan as a result of any consummation of the Merger.   Also, our Board of Directors and Compensation Committee have adopted a Transaction Bonus Plan (the “Transaction Bonus Plan”), which provides for certain bonus payments to be made, upon any consummation of a qualifying change of control transaction such as the Merger, to certain participants as shall be determined from time to time by the Compensation Committee of our Board of Directors. The aggregate value of the bonuses payable under the Transaction Bonus Plan shall be the greater of (i) $1,000,000 or (ii) ten percent of the net proceeds received in connection with a qualifying change of control transaction such as the Merger, and the percentage of such bonus pool awarded to each eligible participant shall be determined from time to time by our Compensation Committee.   Litigation   In 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 and $50,000 for both of the three and six months ended June 30, 2017 and 2016, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.   From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

3000000

1735000

1000000

2735000

1250000

842000

2092000

0.10

602000

441000

346000

405000

18000

34000

294000

20000

44000

341000

190000

153000

9000

16000

128000

4000

17000

169000

2887760

4080026

64326

2701647

71749

2701747

98049

59000

23738

1247530

4080026

2887760

64326

98049

2701647

23738

71749

59000

2701747

1247530

3727000

3022000

1772000

500000

750000

2727000

500000

3727000

3022000

1772000

500000

750000

2727000

500000

1735000

1250000

842000

2092000

73.65

0.075

29.55

5.17

16.50

32.51

16.50

30.90

46.80

29.55

32.51

8000

23738

0.06

258.397875

2067183

1000

2067183

7908

2043445

3.87

890000

1900000

2701747

2701647

2067076

2067176

100847

1831

46676

1690

388365

32788

18334

11252

300

656000

1000 656000 2200000 0.75 2.00

1000

8000000

1100000

200000

P5Y 2021-03-31 2020-08-31 2020-08-31 2020-08-31 2018-04-30 2018-12-31 2019-06-30 2019-05-31 2019-03-31 2018-09-30 1000000 0.10

25000

50000

25000

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.   Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.   Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.   Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including third-party commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for any of the periods presented.   Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.   Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="width: 58px">Level 1:</td> <td style="text-align: justify">Observable market inputs such as quoted prices in active markets;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">●</td> <td>Level 2: </td> <td style="text-align: justify">Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">●</td> <td>Level 3:</td> <td style="text-align: justify">Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>   We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.   Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.   Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.   Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from Insurance Carrier A of $602,000 exceeded 10% of our total accounts receivable balance as of June 30, 2017. Accounts receivable from Insurance Carrier B of $441,000 exceeded 10% of our total accounts receivable balance as of December 31, 2016.   Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.   Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.   Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.   Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock as reported on The NASDAQ Capital Market on the date of grant.   In March 2016, the Financial Accounting Standards Board (“FASB”) issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award or recognize forfeitures at the time an award is canceled and forfeited. The standard became effective for us on January 1, 2017. We elected to change our policy regarding forfeitures to recognize if and when an award is canceled and forfeited rather than estimating forfeitures up front. The impact from implementing this policy change was to reduce retained earnings and increase additional paid-in capital by $57,000.   Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Cost of services</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">9</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">4</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">18</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">20</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Sales and marketing</td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">44</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">128</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">169</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">294</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total non-cash stock compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">190</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">405</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Common stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Restricted stock units</td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Common stock warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Series F preferred stock convertible into common stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Excluded potentially dilutive securities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   Segments. We have determined that we operate in one segment for financial reporting purposes.   Recent Accounting Pronouncements. In July 2017, the FASB issued an accounting standards update regarding earnings per share, distinguishing liabilities from equity and derivatives and hedging. Part 1 of the update addresses the complexity of accounting for certain financial instruments with down-round features, such as anti-dilution provisions of common stock warrant contracts that can require liability classification and subsequent mark-to-market accounting for these securities. As a result of this update, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, which means that derivative accounting treatment and liability classification are no longer required. The amendment requires the effect of a down round feature to be treated as a dividend and as a reduction of income available to common shareholders when computing basic earnings per share when the feature is triggered. In addition, convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features, including related EPS guidance. Part II of the update addresses certain content that is pending or deferred and has no accounting effect. The amendments in Part I of the update are effective for all public entities for the first interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. We are currently analyzing the details of the update and have not yet determined what impact, if any, the adoption of this update may have on our consolidated financial statements.   In May 2017, the FASB issued an accounting standards update regarding stock-based compensation. The purpose of the update is to provide clarity regarding when an entity should apply modification accounting from changes that an entity makes to the terms or conditions of share-based payment awards. The update is effective for all entities for the first interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.   In January 2017, the FASB issued a new accounting standard that eliminates Step 2 of the goodwill impairment test currently required under GAAP. Instead, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill that had been allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. This standard is effective for public business entities for the first interim and annual reporting periods beginning after January 1, 2020, with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.   Also in January 2017, the FASB issued a new accounting standard that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. This update is effective on January 1, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.   In November 2016, the FASB issued new accounting guidance governing restricted cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The amendments in this guidance should be applied using a retrospective transition method to each period presented. This guidance is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In August 2016, the FASB issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In February 2016, the FASB issued a new accounting standard regarding leases, which requires lessees to recognize on their balance sheets a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The standard also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The standard requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The standard is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this standard will have on our consolidated financial statements.   In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.   In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We have nearly completed our detailed assessment of the impact that this guidance will have on our consolidated financial statements, with additional analysis currently ongoing. Based on our current assessment, we expect the majority of the amounts that have historically been recognized as bad debt expense, primarily related to patient responsibility, will be reflected as a reduction of the transaction price originally recognized and therefore as a reduction in revenue. We will adopt the new guidance beginning January 2018.   Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

3. CASH AND SHORT-TERM INVESTMENTS   As of June 30, 2017, we held $3.0 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">As of June 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">As of December 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Unrealized</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="padding-bottom: 1.5pt; text-align: center">Fair</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Unrealized</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="padding-bottom: 1.5pt; text-align: center">Fair</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Cost</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Gains</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Losses</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Cost</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Gains</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Losses</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Cash and money market securities</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">1,772</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">1,772</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">2,727</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">2,727</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Commercial paper</td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Certificates of deposit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">750</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">750</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,022</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,022</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,727</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,727</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   There were no realized gains or losses for the periods ended June 30, 2017 or 2016.

4. FAIR VALUE MEASUREMENTS   The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2017 and December 31, 2016 and the classification by level of input within the fair value hierarchy defined above (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="11" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">June 30, 2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; padding-left: 10pt">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">2,092</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">842</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Short-term investments</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Cash equivalents</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,092</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">842</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,250</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="11" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">December 31, 2016</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; padding-left: 10pt">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,735</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,735</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Short-term investments</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,000</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,000</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Cash equivalents</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,735</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,735</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,000</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   The carrying amounts of accounts receivable, accounts payable, accrued expenses, capital leases and the secured promissory note approximate fair value due primarily to the short-term nature of these financial instruments.

5. STOCKHOLDERS’ EQUITY   Series A through E Convertible Preferred Stock and Warrant Financings   Between 2012 and 2015, we executed several financing transactions whereby we issued convertible preferred stock and warrants to purchase common stock to investors. As of December 31, 2016, none of the Series A through E convertible preferred stock remained outstanding. For as long as the Series A warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at a price per share below the $73.65 exercise price of the Series A warrants, unless waivers from the Series A investors are obtained. Until the time that less than 7.5% of the Series B, C and E warrants remain unexercised through their expiration date, except under certain permitted circumstances, we may not issue, or enter into any agreement to issue, common stock or common stock equivalents at prices per share below the $29.55, $29.55 and $32.51 exercise prices of the Series B, C and E warrants, respectively, unless waivers from the Series B, C and E investors are obtained. In addition, until there are no longer Series A, C and E warrants outstanding, we may not sell any variable rate securities except for certain exempt issuances.   Series E Modifications   On February 4, 2016, we entered into a Series E 6% Convertible Preferred Stock Repurchase Agreement (the “Repurchase Agreement”) with the Series E Investors. Pursuant to the terms of the Repurchase Agreement, we agreed to pay each Series E Investor $300 per share of Series E Preferred Stock, or approximately $656,000, in consideration for the right to repurchase the Series E Investor’s Series E Preferred Stock at a price per share of $1,000 (the “Repurchase Price”), which was the original price per share paid by the Series E Investors for their Series E Preferred Stock in February 2015. We recognized the $656,000 payment as a deemed dividend paid to the Series E investors.   Immediately following the closing of our Series F public offering discussed below, we paid $2.2 million to the Series E Investors to repurchase all of the outstanding Series E Preferred Stock, in accordance with the terms of the Repurchase Agreement. Since almost none of the Series E Preferred Stock had converted by the time we repurchased the Series E Preferred Stock, the original $890,000 beneficial conversion feature that we recognized as a deemed dividend in 2015 was reversed as a return of capital from the Series E Preferred stockholders to the common stockholders.   Series F Convertible Preferred Stock and Warrants Financing   On March 24, 2016 (the “Series F Closing”), we closed an underwritten public offering (the “Series F Offering”) and issued 8,000 immediately separable units of securities to investors, with each unit consisting of: (i) one share of Series F convertible preferred stock (“Series F Preferred Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $3.87, which was 75% of the consolidated closing bid price of our common stock on The NASDAQ Capital Market on March 18, 2016, the date we executed the underwriting agreement (“UA date”); and (ii) 258.397875 warrants, each to purchase one share of our common stock at an exercise price per share equal to $5.17 (“Series F Warrants”), which was 100% of the consolidated closing bid price of our common stock on The NASDAQ Capital Market on the UA date. The Series F Preferred Stock, the Series F Warrants, and the shares of common stock underlying the Series F Preferred Stock and Series F Warrants were registered on Form S-1, which was declared effective by the SEC on March 18, 2016. The Series F Preferred Stock was immediately convertible and the Series F Warrants were immediately exercisable for shares of common stock and have a term of five years. The Series F Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. In total, there were 2,067,183 shares of common stock issuable upon conversion of the Series F Preferred Stock and up to 2,067,183 shares of common stock issuable upon exercise of the Series F Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds received by us of $8.0 million. Total offering-related costs paid through December 31, 2016 were $1.1 million, resulting in net proceeds recognized of $6.9 million. Given that the effective conversion price of the Series F Preferred Stock was below the closing market price of our common stock at the time of the Series F Closing, we recognized a beneficial conversion feature in the amount of $1.9 million. Since the Series F Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings at closing. Also, from the time of the Series F Closing through June 30, 2017, 7,908 shares of the Series F Preferred Stock have converted into 2,043,445 shares of common stock, leaving 92 shares of Series F Preferred Stock (representing 23,738 shares of common stock) unconverted.   The Series F Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to distributions upon our dissolution, liquidation or winding-up. Until the volume weighted average price of our common stock on NASDAQ exceeds 200% of the conversion price of the Series F Preferred Stock for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, the Series F Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to certain limitations. Also, the Company can force holders of Series F Preferred Stock to convert into our common stock if the volume-weighted average price of our common stock exceeds 200% of the Series F Preferred Stock conversion price for any 20 of 30 consecutive trading days, and the daily dollar trading volume during such period exceeds $200,000 per trading day, subject to certain other conditions. The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).   The Series F Warrants have a 5-year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series F Warrants. The Series F Warrants are not subject to price based anti-dilution protection. The Series F Warrants are listed on The NASDAQ Capital Market under the trading symbol “CBMXW.”   Depending on the circumstances, upon a change in control constituting a “Fundamental Transaction” (as defined in the Series F Warrants), the holders of Series F Preferred Stock may be entitled to a 30% premium and the holders of Series F Warrants may have the right to require either that the Company purchase the Series F Warrants for an amount in cash that is determined in accordance with a formula set forth in the Series F Warrants or that the successor assumes and replaces the Series F Warrants with substantially equivalent warrants of the successor.   Common Stock Purchase Warrants Repurchase Agreement   On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings. Pursuant to the terms of the Warrants Repurchase Agreement, we have agreed to repurchase such Warrants from each Holder upon execution of a “Fundamental Transaction” (as defined in such Warrants) at various negotiated prices per Warrant share as set forth in the Warrants Repurchase Agreement. The Warrants Repurchase Agreement obligates us to repurchase half of such Warrants upon the announcement of a Fundamental Transaction. On July 31, 2017, we announced that we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Invitae Corporation (“Invitae”) and Coronado Merger Sub, Inc., a wholly owned subsidiary of Invitae (“Merger Sub”), pursuant to which Invitae plans to acquire us in an all-stock transaction in which Merger Sub will merge with and into us (the “Merger”). The Merger is considered a Fundamental Transaction under the Warrants Repurchase Agreement and, as a result of entering into and announcing the Merger Agreement, and pursuant to the terms of the Warrants Repurchase Agreement, we repurchased one half of such outstanding Warrants on August 3, 2017, for approximately $230,000 of cash consideration. Under the terms of the Warrants Repurchase Agreement, we will be obligated to repurchase the remaining half of such Warrants within three business days of any closing of the Merger. In addition, upon any closing of the Merger, all Securities Purchase Agreements and Registration Rights Agreements associated with the original issuances of such Warrants will be terminated and the various restrictions set forth therein will no longer be of any force or effect. In connection with entering into the Warrants Repurchase Agreement, we were granted certain consents and waivers relating to the Merger. If the Merger is consummated, we will be obligated to repurchase the remaining outstanding Warrants for approximately $230,000 which will be due within three business days of closing the Merger. In the event that we do not close the Merger or any other Fundamental Transaction, for whatever reason, then the remaining half of such Warrants will remain issued and outstanding. See Note 7 below.   Warrants   Outstanding warrants to purchase common stock are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Shares of Common Stock Issuable from Warrants Outstanding as of</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">June 30,</td> <td> </td> <td colspan="3" style="text-align: center">December 31,</td> <td> </td> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Equity-classified warrants:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; padding-left: 10pt">March 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,067,076</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,067,176</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5.17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center">March 2021</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">April 2015</td> <td> </td> <td> </td> <td style="text-align: right">100,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,847</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">16.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">April 2015</td> <td> </td> <td> </td> <td style="text-align: right">1,831</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,831</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">32.51</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">February 2015</td> <td> </td> <td> </td> <td style="text-align: right">46,676</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,676</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">16.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">June 2014</td> <td> </td> <td> </td> <td style="text-align: right">1,690</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,690</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">30.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">December 2013</td> <td> </td> <td> </td> <td style="text-align: right">388,365</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">388,365</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">46.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">June 2013</td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">June 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">May 2013</td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">May 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">March 2013</td> <td> </td> <td> </td> <td style="text-align: right">18,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,334</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">March 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">October 2012</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,252</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,252</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">29.55</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">September 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,701,647</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,701,747</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The number of warrants set forth in the table above are as of June 30, 2017 and December 31, 2016 and do not reflect the repurchase of half of the Warrants we completed on August 3, 2017.

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.   Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including third-party commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. No single customer exceeded 10% of revenues for any of the periods presented.

Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="width: 58px">Level 1:</td> <td style="text-align: justify">Observable market inputs such as quoted prices in active markets;</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">●</td> <td>Level 2: </td> <td style="text-align: justify">Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">●</td> <td>Level 3:</td> <td style="text-align: justify">Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>   We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.

Impairment of Long-Lived Assets. Long-lived assets and intangible assets are reviewed for potential impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the sum of the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss equal to the excess of the asset’s carrying value over its fair value is recorded. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows.

Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.

Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from Insurance Carrier A of $602,000 exceeded 10% of our total accounts receivable balance as of June 30, 2017. Accounts receivable from Insurance Carrier B of $441,000 exceeded 10% of our total accounts receivable balance as of December 31, 2016.   Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.

Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.   Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.

Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock as reported on The NASDAQ Capital Market on the date of grant.   In March 2016, the Financial Accounting Standards Board (“FASB”) issued guidance regarding employee share-based payment accounting. The guidance is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and provides the choice for companies to estimate forfeitures during the vesting period of an award or recognize forfeitures at the time an award is canceled and forfeited. The standard became effective for us on January 1, 2017. We elected to change our policy regarding forfeitures to recognize if and when an award is canceled and forfeited rather than estimating forfeitures up front. The impact from implementing this policy change was to reduce retained earnings and increase additional paid-in capital by $57,000.   Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Cost of services</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">9</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">4</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">18</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">20</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Sales and marketing</td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">44</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">128</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">169</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">294</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total non-cash stock compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">190</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">405</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Common stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Restricted stock units</td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Common stock warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Series F preferred stock convertible into common stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Excluded potentially dilutive securities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

Recent Accounting Pronouncements. In July 2017, the FASB issued an accounting standards update regarding earnings per share, distinguishing liabilities from equity and derivatives and hedging. Part 1 of the update addresses the complexity of accounting for certain financial instruments with down-round features, such as anti-dilution provisions of common stock warrant contracts that can require liability classification and subsequent mark-to-market accounting for these securities. As a result of this update, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock, which means that derivative accounting treatment and liability classification are no longer required. The amendment requires the effect of a down round feature to be treated as a dividend and as a reduction of income available to common shareholders when computing basic earnings per share when the feature is triggered. In addition, convertible instruments with embedded conversion options that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features, including related EPS guidance. Part II of the update addresses certain content that is pending or deferred and has no accounting effect. The amendments in Part I of the update are effective for all public entities for the first interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. We are currently analyzing the details of the update and have not yet determined what impact, if any, the adoption of this update may have on our consolidated financial statements.   In May 2017, the FASB issued an accounting standards update regarding stock-based compensation. The purpose of the update is to provide clarity regarding when an entity should apply modification accounting from changes that an entity makes to the terms or conditions of share-based payment awards. The update is effective for all entities for the first interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.   In January 2017, the FASB issued a new accounting standard that eliminates Step 2 of the goodwill impairment test currently required under GAAP. Instead, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill that had been allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. This standard is effective for public business entities for the first interim and annual reporting periods beginning after January 1, 2020, with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.   Also in January 2017, the FASB issued a new accounting standard that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. This update is effective on January 1, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.   In November 2016, the FASB issued new accounting guidance governing restricted cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The amendments in this guidance should be applied using a retrospective transition method to each period presented. This guidance is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In August 2016, the FASB issued new accounting guidance aimed at reducing the existing diversity in GAAP regarding how certain cash receipts and cash payments are classified in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is also permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated statements of cash flows.   In February 2016, the FASB issued a new accounting standard regarding leases, which requires lessees to recognize on their balance sheets a right-of-use asset, representing their right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The standard also requires qualitative and quantitative disclosures designed to assess the amount, timing and uncertainty of cash flows arising from leases. The standard requires the use of a modified retrospective transition approach, which includes a number of optional practical expedients that entities may elect to apply. The standard is effective for us beginning January 1, 2019, and we are currently evaluating the impact that this standard will have on our consolidated financial statements.   In January 2016, the FASB issued accounting guidance regarding recognition and measurement of financial assets and financial liabilities. This guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. We do not expect the adoption of this guidance to have a significant impact on our consolidated financial statements.   In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from GAAP. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in 2015, the FASB voted to defer the effective date of the new guidance for one year. We have nearly completed our detailed assessment of the impact that this guidance will have on our consolidated financial statements, with additional analysis currently ongoing. Based on our current assessment, we expect the majority of the amounts that have historically been recognized as bad debt expense, primarily related to patient responsibility, will be reflected as a reduction of the transaction price originally recognized and therefore as a reduction in revenue. We will adopt the new guidance beginning January 2018.

Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Cost of services</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">9</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">4</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">18</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">20</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Sales and marketing</td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">44</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">128</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">169</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">294</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total non-cash stock compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">153</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">190</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">405</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

The following table reflects the excluded dilutive securities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td> <td> </td> <td colspan="7" style="text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%">Common stock options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">64,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">71,749</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Restricted stock units</td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">98,049</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Common stock warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,647</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,701,747</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Series F preferred stock convertible into common stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,738</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,247,530</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Excluded potentially dilutive securities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,887,760</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,080,026</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

Cash, cash equivalents and short-term investments consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">As of June 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">As of December 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Unrealized</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="padding-bottom: 1.5pt; text-align: center">Fair</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Unrealized</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="padding-bottom: 1.5pt; text-align: center">Fair</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Cost</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Gains</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Losses</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Cost</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Gains</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Losses</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Cash and money market securities</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">1,772</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">1,772</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">2,727</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 4%; text-align: right">2,727</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Commercial paper</td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Certificates of deposit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">750</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">750</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,022</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,022</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,727</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,727</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2017 and December 31, 2016 and the classification by level of input within the fair value hierarchy defined above (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="11" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">June 30, 2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; padding-left: 10pt">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">2,092</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">842</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Short-term investments</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Cash equivalents</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,092</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">842</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,250</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="11" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">December 31, 2016</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; padding-left: 10pt">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,735</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">1,735</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Short-term investments</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,000</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,000</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Cash equivalents</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,735</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,735</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,000</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="border-bottom: black 2.25pt double"> </td></tr> </table>

Outstanding warrants to purchase common stock are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Shares of Common Stock Issuable from Warrants Outstanding as of</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">June 30,</td> <td> </td> <td colspan="3" style="text-align: center">December 31,</td> <td> </td> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Equity-classified warrants:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; padding-left: 10pt">March 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,067,076</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,067,176</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5.17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center">March 2021</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">April 2015</td> <td> </td> <td> </td> <td style="text-align: right">100,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,847</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">16.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">April 2015</td> <td> </td> <td> </td> <td style="text-align: right">1,831</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,831</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">32.51</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">February 2015</td> <td> </td> <td> </td> <td style="text-align: right">46,676</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,676</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">16.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">August 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">June 2014</td> <td> </td> <td> </td> <td style="text-align: right">1,690</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,690</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">30.90</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">December 2013</td> <td> </td> <td> </td> <td style="text-align: right">388,365</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">388,365</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">46.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">June 2013</td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">June 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">May 2013</td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">32,788</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">May 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">March 2013</td> <td> </td> <td> </td> <td style="text-align: right">18,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,334</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">March 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">October 2012</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,252</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,252</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">29.55</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">September 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,701,647</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,701,747</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

6900000 0.125 1500000 25000 2018 2.00 1.00 CBMX

1. OVERVIEW AND BACKGROUND   CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In August 2007, we split-off from Acacia and became publicly traded on The NASDAQ Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.   Description of the Company   We are a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. We strive to provide best-in-class clinical laboratory support to healthcare professionals, allowing them to maximize the clinical utility of their patients’ test results and to optimize patient care. Our testing focuses on advanced technologies, including single nucleotide polymorphism, or SNP, chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Our approach to testing is to offer sophisticated technology along with high-quality clinical support to our ordering physicians and their patients. Our laboratory facilities and corporate headquarters are located in Irvine, California.   We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.   Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and notes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2016, as reported by us in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2017. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of June 30, 2017, and results of operations and cash flows for the interim periods presented. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the entire year.   Going Concern Analysis   We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. As a result, these conditions raise substantial doubt regarding our ability to continue as a going concern beyond twelve months from the date of this filing. However, as of June 30, 2017, we had cash, cash equivalents and short-term investments of $3.0 million. Also, the combination of continued revenue and cash reimbursement growth we have experienced over the past several quarters, coupled with improved gross margins and cost containment of expenses leads management to believe that it is probable that our cash resources will be sufficient to meet our cash requirements for current operations through and beyond the fourth quarter of 2017, when we anticipate achieving cash flow break-even status. If necessary, management also believes that it is probable that external sources of debt and/or equity financing could be obtained based on management’s history of being able to raise capital coupled with current favorable market conditions. As a result of both management’s plans and current favorable trends in improving cash flow, we believe the initial conditions which raised substantial doubt regarding our ability to continue as a going concern have been alleviated. Therefore, the accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and on terms acceptable to us, or at all.   The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. While we believe in the viability of our strategy to generate sufficient revenue and cash reimbursement, control costs and our ability to raise additional funds if necessary, there can be no assurances to that effect. Our ability to continue as a going concern is dependent upon our ability to further implement our business plan, generate sufficient revenues and cash reimbursement and to control operating expenses.   Risks   Our business operations are also subject to certain risks and uncertainties, including:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">● </td> <td style="text-align: justify">market acceptance of our services;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">technological advances that may make our services obsolete or less competitive;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">increases in operating costs, including costs for supplies, personnel and equipment;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">variability in third-party reimbursement of our tests;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">the availability and cost of capital; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">governmental regulation that may restrict our business.</td></tr> </table>   Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned services, could have a material adverse effect on our business and operating results.

230000

Segments. We have determined that we operate in one segment for financial reporting purposes.

0.001

0.50

0.20

0.30 On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings.

57000

0001383183

The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

2673756

2918726

2673756

2918726

8478000

8119000

30000

597000

523000

7851000

7566000

174000

170000

599000

368000

3351000

4006000

1984000

2167000

145000

126000

50000

72000

1789000

1969000

100000

49000

1689000

1920000

8478000

8119000

6494000

5952000

-102589000

-103534000

109068000

109471000

15000

8028000

6079000

3107000

4241000

56000

100000

58000

27000

7972000

5979000

3049000

4214000

-889000

-2703000

-1226000

-372000

8917000

8782000

4333000

4613000

50000

25000

3519000

3112000

1586000

1855000

2038000

2477000

1141000

1016000

170000

292000

149000

85000

3140000

2851000

1432000

1632000

-888000

-2726000

-1235000

-370000

1000

-23000

-9000

2000

10000

35000

17000

3000

11000

12000

8000

5000

-888000

-4369000

-1235000

-370000

890000

-656000 -1877000 -0.31 -3.89 -0.89 -0.13

0.79

-0.58 -1.67

-0.31

-2.43

-0.89

-0.13

2838521

1122975

1382019

2915303

-607000

-2544000

233000

151000

-235000

22000

956000

687000

301000

205000

346000

405000

122000

130000

996000

2603000

2499000

7748000

1499000

4998000

19000

23000

147000

-94000

4015000

94000

95000

-2842000

1048000

8000000

295000

4074000

20000 10000 1877000

-890000

57000

63000

6000

7. SUBSEQUENT EVENTS   On July 31, 2017, we entered into the Merger Agreement with Invitae, pursuant to which Invitae plans to acquire us through an all-stock Merger. The Merger is subject to certain closing conditions, as set forth in the Merger Agreement, including, among others, obtaining certain regulatory approvals, approval from our stockholders, Invitae’s registration of common stock to be used to acquire us, and at least 90% participation in a Series F Warrants exchange offer that will be conducted by Invitae in connection with the Merger.   The Merger Agreement contains certain termination rights for both us and Invitae, including, among others, if the Merger is not consummated on or before January 31, 2018 (unless due to the terminating party’s action or failure to act or SEC delay) or if the approval of our stockholders is not obtained. If the Merger Agreement is terminated by either us or Invitae as a result of a breach by the other party of any of such other party’s representations, warranties or covenants, or because the occurrence of a material adverse effect applicable to such party was the sole failed condition to closing, or if the Merger Agreement is terminated by Invitae as a result of the failure of our stockholders to approve the Merger Agreement or as a result of an adverse change in the recommendation of our board of directors, then the defaulting party will be obligated to reimburse the other party’s third party expenses up to a maximum of $400,000. The Merger Agreement further provides that, upon termination of the Merger Agreement under specified circumstances, including, among others, termination of the Merger Agreement as a result of an adverse change in the recommendation of our board of directors after receiving a bona fide alternative acquisition proposal or termination of the Merger Agreement as a result of our stockholders not approving the Merger Agreement following disclosure of a bona fide acquisition proposal after which we are sold within 12 months, we may be required to pay to Invitae a termination fee of up to $1.4 million.   The foregoing description of the Merger Agreement is not a complete description of all of the parties’ rights and obligations under the Merger Agreement and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to our Current Report on Form 8-K filed with the SEC on July 31, 2017.   As a result of entering into and announcing the Merger Agreement, and pursuant to the terms of the Warrants Repurchase Agreement, On August 3, 2017, we repurchased one-half of the outstanding Warrants for approximately $230,000 of cash consideration. The remaining half will be due within three business days of any closing of the Merger.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

1400000

0.90

2017

The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).

400000

EX-101.SCH 7 cbmx-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Overview and Background link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash and Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Cash and Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Overview and Background (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Cash and Short-Term Investments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Cash and Short-Term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cbmx-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cbmx-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cbmx-20170630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series F Convertible Preferred Stock [Member] Range [Axis] Maximum [Member] Minimum [Member] Concentration Risk Benchmark [Axis] Sales Revenue, Net [Member] Customer [Axis] No Single Customer [Member] Accounts Receivable [Member] Concentration Risk Type [Axis] Commercial Insurance Carrier A [Member] Commercial Insurance Carrier B [Member] Commercial Insurance Carrier B [Member] Income Statement Location [Axis] Cost of Services [Member] Research and Development [Member] Sales and Marketing [Member] General and Administrative [Member] Antidilutive Securities [Axis] Common Stock Options [Member] Common Stock Warrants [Member] Cash and Cash Equivalents [Axis] Cash and Money Market Securities [Member] Investment Type [Axis] Commercial Paper [Member] Certificates of Deposit [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Class of Warrant or Right [Axis] Series A Warrants [Member] Series B Warrants [Member] Series C Warrants [Member] Series E 6% Percent Convertible Preferred Stock [Member] Series E Investors [Member] Series F Offering [Member] Series F Convertible Preferred Stock And Warrants Financing [Member] Equity Components [Axis] Common Stock [Member] March, 2016 [Member] April 2015 [Member] April 2015 [Member] February 2015 [Member] June 2014 [Member] December 2013 [Member] June 2013 [Member] May 2013 [Member] March 2013 [Member] October 2012 [Member] Other Commitments [Axis] Transaction Bonus Plan [Member] Litigation [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] Warrant Repurchase Agreements [Member] Series E Warrants [Member] Series F Warrants [Member] Restricted Stock Units [Member] Series F Preferred Stock Convertible into Common Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Merger Agreement [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Short-term investments Accounts receivable, net of allowance for doubtful accounts of $227 and $232 Supplies Prepaid expenses and other assets Total current assets Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable, accrued expenses and other Current portion, long-term debt Total current liabilities Capital lease obligations, net of current portion Deferred rent Total liabilities Commitments and contingencies (Note 6) Stockholders' equity: Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 92 and 969 issued and outstanding Common stock; $0.001 par value; 50,000,000 shares authorized; 2,918,726 and 2,673,756 shares issued and outstanding Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Allowance for doubtful accounts Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock ,shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues: Diagnostic services Royalties Total revenues Operating expenses: Cost of services Research and development Sales and marketing General and administrative Patent amortization and royalties Total operating expenses Operating loss Other income (expense): Interest income Interest expense Total other income (expense) Net loss Deemed dividend from issuing Series F convertible preferred stock and warrants Deemed dividend paid for right to repurchase Series E convertible preferred stock Deemed dividend from issuing and modifying Series E convertible preferred stock and warrants Net loss attributable to common stockholders Basic and diluted net loss per share Deemed dividend from issuing Series F convertible preferred stock Deemed dividend paid for right to repurchase Series E convertible preferred stock Deemed dividend from issuing and modifying Series E convertible preferred stock Basic and diluted net loss per share attributable to common stockholders Basic and diluted weighted average common shares outstanding Statement of Comprehensive Income [Abstract] Net loss Unrealized gain on available-for-sale investments Total comprehensive loss Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash flows from operating activities: Depreciation and amortization Non-cash stock compensation Provision for bad debts Changes in assets and liabilities: Accounts receivable Supplies, prepaid expenses and other assets Accounts payable, accrued expenses and other Net cash flows from operating activities Investing activities: Purchases of property and equipment Proceeds from sale of property and equipment Purchase of available-for-sale investments Sale of available-for-sale investments Net cash flows from investing activities Financing activities: Proceeds from issuance of Series F convertible preferred stock and common stock warrants Costs from issuance of Series F convertible preferred stock and common stock warrants Repurchase of Series E convertible prefered stock and dividends Repayments of long-term debt Net cash flows from financing activities Change in cash and cash equivalents Cash and cash equivalents, beginning Cash and cash equivalents, ending Non-cash financing activities: Property and equipment purchased under capital lease Adjustments to paid-in capital and retained earnings from change in accounting principle Deemed dividends from issuing Series E convertible preferred stock Deemed dividends from issuing Series F convertible preferred stock Accrued public offering costs Accrued property, plant and equipment Organization, Consolidation and Presentation of Financial Statements [Abstract] Overview and Background Accounting Policies [Abstract] Summary of Significant Accounting Policies Cash and Cash Equivalents [Abstract] Cash and Short-Term Investments Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Stockholders' Equity EX-101.PRE 11 cbmx-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 07, 2017
Document And Entity Information
Entity Registrant Name	CombiMatrix Corp
Entity Central Index Key	0001383183
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,918,726
Trading Symbol	CBMX
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,022	$ 2,727
Short-term investments		1,000
Accounts receivable, net of allowance for doubtful accounts of $227 and $232	4,006	3,351
Supplies	368	599
Prepaid expenses and other assets	170	174
Total current assets	7,566	7,851
Property and equipment, net	523	597
Other assets	30	30
Total assets	8,119	8,478
Current liabilities:
Accounts payable, accrued expenses and other	1,920	1,689
Current portion, long-term debt	49	100
Total current liabilities	1,969	1,789
Capital lease obligations, net of current portion	72	50
Deferred rent	126	145
Total liabilities	2,167	1,984
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 92 and 969 issued and outstanding
Common stock; $0.001 par value; 50,000,000 shares authorized; 2,918,726 and 2,673,756 shares issued and outstanding	15	15
Additional paid-in capital	109,471	109,068
Accumulated other comprehensive loss
Accumulated deficit	(103,534)	(102,589)
Total stockholders' equity	5,952	6,494
Total liabilities and stockholders' equity	8,119	8,478
Series F Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5,000,000 shares authorized; Series F - 8,000 shares authorized; 92 and 969 issued and outstanding

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts	$ 227	$ 232
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock ,shares issued	2,918,726	2,673,756
Common stock, shares outstanding	2,918,726	2,673,756
Series F Convertible Preferred Stock [Member]
Convertible preferred stock, shares authorized	8,000	8,000
Convertible preferred stock, shares issued	92	969
Convertible preferred stock, shares outstanding	92	969

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Diagnostic services	$ 4,214	$ 3,049	$ 7,972	$ 5,979
Royalties	27	58	56	100
Total revenues	4,241	3,107	8,028	6,079
Operating expenses:
Cost of services	1,632	1,432	3,140	2,851
Research and development	85	149	170	292
Sales and marketing	1,016	1,141	2,038	2,477
General and administrative	1,855	1,586	3,519	3,112
Patent amortization and royalties	25	25	50	50
Total operating expenses	4,613	4,333	8,917	8,782
Operating loss	(372)	(1,226)	(889)	(2,703)
Other income (expense):
Interest income	5	8	11	12
Interest expense	(3)	(17)	(10)	(35)
Total other income (expense)	2	(9)	1	(23)
Net loss	(370)	(1,235)	(888)	(2,726)
Deemed dividend from issuing Series F convertible preferred stock and warrants				(1,877)
Deemed dividend paid for right to repurchase Series E convertible preferred stock				(656)
Deemed dividend from issuing and modifying Series E convertible preferred stock and warrants				890
Net loss attributable to common stockholders	$ (370)	$ (1,235)	$ (888)	$ (4,369)
Basic and diluted net loss per share	$ (0.13)	$ (0.89)	$ (0.31)	$ (2.43)
Deemed dividend from issuing Series F convertible preferred stock				(1.67)
Deemed dividend paid for right to repurchase Series E convertible preferred stock				(0.58)
Deemed dividend from issuing and modifying Series E convertible preferred stock				0.79
Basic and diluted net loss per share attributable to common stockholders	$ (0.13)	$ (0.89)	$ (0.31)	$ (3.89)
Basic and diluted weighted average common shares outstanding	2,915,303	1,382,019	2,838,521	1,122,975

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (370)	$ (1,235)	$ (888)	$ (2,726)
Unrealized gain on available-for-sale investments				2
Total comprehensive loss	$ (1,235)	$ (370)	$ (888)	$ (2,724)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities:
Net loss	$ (888)	$ (2,726)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	122	130
Non-cash stock compensation	346	405
Provision for bad debts	301	205
Changes in assets and liabilities:
Accounts receivable	(956)	(687)
Supplies, prepaid expenses and other assets	235	(22)
Accounts payable, accrued expenses and other	233	151
Net cash flows from operating activities	(607)	(2,544)
Investing activities:
Purchases of property and equipment	(23)	(147)
Proceeds from sale of property and equipment	19
Purchase of available-for-sale investments	(1,499)	(4,998)
Sale of available-for-sale investments	2,499	7,748
Net cash flows from investing activities	996	2,603
Financing activities:
Proceeds from issuance of Series F convertible preferred stock and common stock warrants		8,000
Costs from issuance of Series F convertible preferred stock and common stock warrants		(1,048)
Repurchase of Series E convertible prefered stock and dividends		(2,842)
Repayments of long-term debt	(94)	(95)
Net cash flows from financing activities	(94)	4,015
Change in cash and cash equivalents	295	4,074
Cash and cash equivalents, beginning	2,727	653
Cash and cash equivalents, ending	3,022	4,727
Non-cash financing activities:
Property and equipment purchased under capital lease	63	6
Adjustments to paid-in capital and retained earnings from change in accounting principle	57
Deemed dividends from issuing Series E convertible preferred stock		(890)
Deemed dividends from issuing Series F convertible preferred stock		1,877
Accrued public offering costs		10
Accrued property, plant and equipment		$ 20

XML 18 R7.htm IDEA: XBRL DOCUMENT

Overview and Background

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Overview and Background

1. OVERVIEW AND BACKGROUND

Description of the Company

Basis of Presentation

Going Concern Analysis

Risks

Our business operations are also subject to certain risks and uncertainties, including:

	●	market acceptance of our services;

	●	technological advances that may make our services obsolete or less competitive;

	●	increases in operating costs, including costs for supplies, personnel and equipment;

	●	variability in third-party reimbursement of our tests;

	●	the availability and cost of capital; and

	●	governmental regulation that may restrict our business.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Cost of services	$	9	$	4	$	18	$	20
Research and development		-		-		-		-
Sales and marketing		16		17		34		44
General and administrative		128		169		294		341
Total non-cash stock compensation	$	153	$	190	$	346	$	405

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Common stock options		64,326		71,749		64,326		71,749
Restricted stock units		98,049		59,000		98,049		59,000
Common stock warrants		2,701,647		2,701,747		2,701,647		2,701,747
Series F preferred stock convertible into common stock		23,738		1,247,530		23,738		1,247,530
Excluded potentially dilutive securities		2,887,760		4,080,026		2,887,760		4,080,026

Segments. We have determined that we operate in one segment for financial reporting purposes.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash and Short-Term Investments

6 Months Ended

Jun. 30, 2017

Cash and Cash Equivalents [Abstract]

Cash and Short-Term Investments

3. CASH AND SHORT-TERM INVESTMENTS

	As of June 30, 2017								As of December 31, 2016
			Unrealized				Fair				Unrealized				Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses		Value

Cash and money market securities	$	1,772	$	-	$	-	$	1,772	$	2,727	$	-	$	-	$	2,727
Commercial paper		500		-		-		500		500		-		-		500
Certificates of deposit		750		-		-		750		500		-		-		500
	$	3,022	$	-	$	-	$	3,022	$	3,727	$	-	$	-	$	3,727

There were no realized gains or losses for the periods ended June 30, 2017 or 2016.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. FAIR VALUE MEASUREMENTS

			Fair Value Measurements
June 30, 2017	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	2,092	$	842	$	1,250	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	2,092	$	842	$	1,250	$	-

			Fair Value Measurements
December 31, 2016	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	1,735	$	1,735	$	-	$	-
Short-term investments		1,000		-		1,000		-
Cash equivalents	$	2,735	$	1,735	$	1,000	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' Equity

5. STOCKHOLDERS’ EQUITY

Series A through E Convertible Preferred Stock and Warrant Financings

Series E Modifications

Series F Convertible Preferred Stock and Warrants Financing

Common Stock Purchase Warrants Repurchase Agreement

Warrants

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
	June 30,		December 31,		Exercise
	2017		2016		Price		Expiration
Equity-classified warrants:
March 2016		2,067,076		2,067,176	$	5.17		March 2021
April 2015		100,847		100,847	$	16.50		August 2020
April 2015		1,831		1,831	$	32.51		August 2020
February 2015		46,676		46,676	$	16.50		August 2020
June 2014		1,690		1,690	$	30.90		April 2018
December 2013		388,365		388,365	$	46.80		December 2018
June 2013		32,788		32,788	$	29.55		June 2019
May 2013		32,788		32,788	$	29.55		May 2019
March 2013		18,334		18,334	$	29.55		March 2019
October 2012		11,252		11,252	$	29.55		September 2018
Total		2,701,647		2,701,747

The number of warrants set forth in the table above are as of June 30, 2017 and December 31, 2016 and do not reflect the repurchase of half of the Warrants we completed on August 3, 2017.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. COMMITMENTS AND CONTINGENCIES

Executive Severance

Litigation

XML 24 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

7. SUBSEQUENT EVENTS

XML 25 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Revenue Recognition

Cash Equivalents and Short-Term Investments

Fair Value Measurements

●	Level 1:	Observable market inputs such as quoted prices in active markets;

●	Level 2:	Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●	Level 3:	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

Impairment of Long-Lived Assets

Derivative Financial Instruments

Concentration of Credit Risks

Accounts Receivable and Allowance for Doubtful Accounts

Stock-Based Compensation

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Cost of services	$	9	$	4	$	18	$	20
Research and development		-		-		-		-
Sales and marketing		16		17		34		44
General and administrative		128		169		294		341
Total non-cash stock compensation	$	153	$	190	$	346	$	405

Net Loss Per Share

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Common stock options		64,326		71,749		64,326		71,749
Restricted stock units		98,049		59,000		98,049		59,000
Common stock warrants		2,701,647		2,701,747		2,701,647		2,701,747
Series F preferred stock convertible into common stock		23,738		1,247,530		23,738		1,247,530
Excluded potentially dilutive securities		2,887,760		4,080,026		2,887,760		4,080,026

Segments

Segments. We have determined that we operate in one segment for financial reporting purposes.

Recent Accounting Pronouncements

Reclassifications

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Cost of services	$	9	$	4	$	18	$	20
Research and development		-		-		-		-
Sales and marketing		16		17		34		44
General and administrative		128		169		294		341
Total non-cash stock compensation	$	153	$	190	$	346	$	405

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table reflects the excluded dilutive securities:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016

Common stock options		64,326		71,749		64,326		71,749
Restricted stock units		98,049		59,000		98,049		59,000
Common stock warrants		2,701,647		2,701,747		2,701,647		2,701,747
Series F preferred stock convertible into common stock		23,738		1,247,530		23,738		1,247,530
Excluded potentially dilutive securities		2,887,760		4,080,026		2,887,760		4,080,026

XML 27 R16.htm IDEA: XBRL DOCUMENT

Cash and Short-Term Investments (Tables)

6 Months Ended

Jun. 30, 2017

Cash and Cash Equivalents [Abstract]

Schedule of Cash, Cash Equivalents and Investments

Cash, cash equivalents and short-term investments consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands):

	As of June 30, 2017								As of December 31, 2016
			Unrealized				Fair				Unrealized				Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses		Value

Cash and money market securities	$	1,772	$	-	$	-	$	1,772	$	2,727	$	-	$	-	$	2,727
Commercial paper		500		-		-		500		500		-		-		500
Certificates of deposit		750		-		-		750		500		-		-		500
	$	3,022	$	-	$	-	$	3,022	$	3,727	$	-	$	-	$	3,727

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis

			Fair Value Measurements
June 30, 2017	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	2,092	$	842	$	1,250	$	-
Short-term investments		-		-		-		-
Cash equivalents	$	2,092	$	842	$	1,250	$	-

			Fair Value Measurements
December 31, 2016	Total		Level 1		Level 2		Level 3
Assets:

Cash equivalents	$	1,735	$	1,735	$	-	$	-
Short-term investments		1,000		-		1,000		-
Cash equivalents	$	2,735	$	1,735	$	1,000	$	-

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights

Outstanding warrants to purchase common stock are as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
	June 30,		December 31,		Exercise
	2017		2016		Price		Expiration
Equity-classified warrants:
March 2016		2,067,076		2,067,176	$	5.17		March 2021
April 2015		100,847		100,847	$	16.50		August 2020
April 2015		1,831		1,831	$	32.51		August 2020
February 2015		46,676		46,676	$	16.50		August 2020
June 2014		1,690		1,690	$	30.90		April 2018
December 2013		388,365		388,365	$	46.80		December 2018
June 2013		32,788		32,788	$	29.55		June 2019
May 2013		32,788		32,788	$	29.55		May 2019
March 2013		18,334		18,334	$	29.55		March 2019
October 2012		11,252		11,252	$	29.55		September 2018
Total		2,701,647		2,701,747

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Overview and Background (Details Narrative) $ in Thousands	Jun. 30, 2017 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and short term investments	$ 3,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)
Cost method, description	The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Reduction of retained earnings and increase additional paid-in capital	$ 57
Number of operating segment \| Segment	1
Sales Revenue, Net [Member] \| No Single Customer [Member]
Concentration credit risk percentage	10.00%
Accounts Receivable [Member] \| Commercial Insurance Carrier A [Member]
Concentration credit risk percentage	10.00%
Fair value, concentration of risk, accounts receivable	$ 602
Accounts Receivable [Member] \| Commercial Insurance Carrier B [Member]
Fair value, concentration of risk, accounts receivable		$ 441
Accounts Receivable [Member] \| Commercial Insurance Carrier B [Member]
Concentration credit risk percentage		10.00%
Minimum [Member]
Equity method investment, ownership percentage	20.00%
Maximum [Member]
Equity method investment, ownership percentage	50.00%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Allocated Share-based Compensation Expense	$ 153	$ 190	$ 346	$ 405
Cost of Services [Member]
Allocated Share-based Compensation Expense	9	4	18	20
Research and Development [Member]
Allocated Share-based Compensation Expense
Sales and Marketing [Member]
Allocated Share-based Compensation Expense	16	17	34	44
General and Administrative [Member]
Allocated Share-based Compensation Expense	$ 128	$ 169	$ 294	$ 341

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Anti-dilutive Securities	2,887,760	4,080,026	2,887,760	4,080,026
Common Stock Options [Member]
Anti-dilutive Securities	64,326	71,749	64,326	71,749
Restricted Stock Units [Member]
Anti-dilutive Securities	98,049	59,000	98,049	59,000
Common Stock Warrants [Member]
Anti-dilutive Securities	2,701,647	2,701,747	2,701,647	2,701,747
Series F Preferred Stock Convertible into Common Stock [Member]
Anti-dilutive Securities	23,738	1,247,530	23,738	1,247,530

XML 34 R23.htm IDEA: XBRL DOCUMENT

Cash and Short-Term Investments (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents, at carrying value	$ 3,022		$ 2,727
Realized investment gains losses	$ 0	$ 0

XML 35 R24.htm IDEA: XBRL DOCUMENT

Cash and Short-Term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Cost	$ 3,022	$ 3,727
Unrealized Gain
Unrealized Loss
Fair Value	3,022	3,727
Commercial Paper [Member]
Cost	500	500
Unrealized Gain
Unrealized Loss
Fair Value	500	500
Certificates of Deposit [Member]
Cost	750	500
Unrealized Gain
Unrealized Loss
Fair Value	750	500
Cash and Money Market Securities [Member]
Cost	1,772	2,727
Unrealized Gain
Unrealized Loss
Fair Value	$ 1,772	$ 2,727

XML 36 R25.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Short-term investments		$ 1,000
Cash equivalents, total	3,000
Fair Value, Measurements, Recurring [Member]
Cash equivalents	2,092	1,735
Short-term investments		1,000
Cash equivalents, total	2,092	2,735
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents	842	1,735
Short-term investments
Cash equivalents, total	842	1,735
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents	1,250
Short-term investments		1,000
Cash equivalents, total	1,250	1,000
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Short-term investments
Cash equivalents, total

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					6 Months Ended	12 Months Ended
	Jul. 11, 2016	Mar. 24, 2016	Mar. 18, 2016	Feb. 04, 2016	Jun. 30, 2017	Dec. 31, 2016
Series F Convertible Preferred Stock [Member]
Convertible preferred stock, shares issued upon conversion		2,067,183			92
Percentage of conversion price of common stock					200.00%
Sold for purchase price equal to per unit		$ 1,000
Gross proceeds received		$ 8,000
Trading volume during such period exceeds					$ 200
Minimum percentage of weighted average price of common stock					200.00%
Preferred stock, description					The Series F investors have agreed to be subject to a blocker that would prevent each of their respective common stock ownership at any given time from exceeding 4.99% of our outstanding common stock (which may be increased on 61 days’ notice, but not above 9.99%).
Warrant premium holders, percent					30.00%
Series F Warrants [Member]
Warrant term					5 years
Series E 6% Percent Convertible Preferred Stock [Member]
Preferred stock, dividend rate, percentage				6.00%
Stock repurchase program, authorized amount per share				$ 300
Stock repurchase program, authorized amount				$ 656
Stock repurchase program, original share price, per share				$ 1,000
Series E Investors [Member]
Payments as deemed dividend paid				$ 656
Repurchase all outstanding stock				2,200
Debt instrument, convertible, beneficial conversion feature				$ 890
Series F Offering [Member]
Debt instrument, convertible, beneficial conversion feature						$ 1,900
Number of common stock issued, shares		8,000
Convertible preferred stock, shares issued upon conversion			1,000
Convertible preferred stock conversion price			$ 3.87
Percentage of conversion price of common stock			75.00%
Total offering related costs paid						1,100
Net proceeds from issuance of stock						$ 6,900
Series F Offering [Member] \| Series F Convertible Preferred Stock [Member]
Convertible preferred stock, shares issued upon conversion					7,908
Series F Offering [Member] \| Common Stock [Member]
Number of common stock issued, shares					23,738
Convertible preferred stock, shares issued upon conversion					2,043,445
Series F Convertible Preferred Stock And Warrants Financing [Member]
Class of warrant or right, exercise price of warrants or rights			$ 5.17
Warrants to purchase of common stock initially			258.397875
Percentage of closing bid price of common stock		100.00%
Warrant Repurchase Agreements [Member]
Common stock purchase warrants repurchase agreement, description	On July 11, 2016, we entered into a Common Stock Purchase Warrants Repurchase Agreement (the “Warrants Repurchase Agreement”) with the holders (the “Holders”) of our outstanding common stock purchase warrants issued in October 2012, March 2013, May 2013, June 2013, June 2014, February 2015 and April 2015 (collectively, the “Warrants”) in connection with our Series A, Series B, Series C and Series E financings.
Repurchase of warrant	$ 230
Maximum [Member] \| Series F Convertible Preferred Stock [Member]
Warrants to purchase of common stock initially		2,067,183
Series A Warrants [Member] \| Maximum [Member]
Share price					$ 73.65
Percentage of warrant remain unexercised through expiration date					7.50%
Series B Warrants [Member]
Class of warrant or right, exercise price of warrants or rights					$ 29.55
Series C Warrants [Member]
Class of warrant or right, exercise price of warrants or rights					29.55
Series E Warrants [Member]
Class of warrant or right, exercise price of warrants or rights					$ 32.51

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Shares of Common Stock Issuable from Warrants Outstanding	2,701,647	2,701,747
March, 2016 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	2,067,076	2,067,176
Exercise Price	$ 5.17	$ 5.17
Expiration term	Mar. 31, 2021
April 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	100,847	100,847
Exercise Price	$ 16.50	$ 16.50
Expiration term	Aug. 31, 2020
April 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,831	1,831
Exercise Price	$ 32.51	$ 32.51
Expiration term	Aug. 31, 2020
February 2015 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	46,676	46,676
Exercise Price	$ 16.50	$ 16.50
Expiration term	Aug. 31, 2020
June 2014 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,690	1,690
Exercise Price	$ 30.90	$ 30.90
Expiration term	Apr. 30, 2018
December 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	388,365	388,365
Exercise Price	$ 46.80	$ 46.80
Expiration term	Dec. 31, 2018
June 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	32,788	32,788
Exercise Price	$ 29.55	$ 29.55
Expiration term	Jun. 30, 2019
May 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	32,788	32,788
Exercise Price	$ 29.55	$ 29.55
Expiration term	May 31, 2019
March 2013 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	18,334	18,334
Exercise Price	$ 29.55	$ 29.55
Expiration term	Mar. 31, 2019
October 2012 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	11,252	11,252
Exercise Price	$ 29.55	$ 29.55
Expiration term	Sep. 30, 2018

XML 39 R28.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2002
Royalty expenses	$ 25	$ 50	$ 25	$ 50
Transaction Bonus Plan [Member]
Maximum bonuses payable	$ 1,000		$ 1,000
Maximum bonuses payable, percent	10.00%		10.00%
Litigation [Member] \| Settlement Agreement [Member]
Litigation settlement percentage					12.50%
Maximum annual litigation payment					$ 1,500
Minimum quarterly litigation payment					$ 25
Patent expire year					2018

XML 40 R29.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	Aug. 03, 2017	Jul. 11, 2016	Jul. 31, 2017	Jun. 30, 2017
Warrant Repurchase Agreements [Member]
Repurchase of warrant		$ 230
Subsequent Event [Member] \| Merger Agreement [Member]
Amount obligated to reimburse by defaulting party				$ 400
Termination fee				$ 1,400
Subsequent Event [Member] \| Merger Agreement [Member] \| Series F Warrants [Member]
Business acquisition of common stock			90.00%
Subsequent Event [Member] \| Warrant Repurchase Agreements [Member]
Repurchase of warrant	$ 230

XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 124 174 1 false 51 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://CBMX/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://CBMX/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://CBMX/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://CBMX/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://CBMX/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://CBMX/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Overview and Background Sheet http://CBMX/role/OverviewAndBackground Overview and Background Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Cash and Short-Term Investments Sheet http://CBMX/role/CashAndShort-termInvestments Cash and Short-Term Investments Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://CBMX/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://CBMX/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Commitments and Contingencies Sheet http://CBMX/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 00000013 - Disclosure - Subsequent Events Sheet http://CBMX/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 00000014 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://CBMX/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://CBMX/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Cash and Short-Term Investments (Tables) Sheet http://CBMX/role/CashAndShort-termInvestmentsTables Cash and Short-Term Investments (Tables) Tables http://CBMX/role/CashAndShort-termInvestments 16 false false R17.htm 00000017 - Disclosure - Fair Value Measurements (Tables) Sheet http://CBMX/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://CBMX/role/FairValueMeasurements 17 false false R18.htm 00000018 - Disclosure - Stockholders' Equity (Tables) Sheet http://CBMX/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://CBMX/role/StockholdersEquity 18 false false R19.htm 00000019 - Disclosure - Overview and Background (Details Narrative) Sheet http://CBMX/role/OverviewAndBackgroundDetailsNarrative Overview and Background (Details Narrative) Details http://CBMX/role/OverviewAndBackground 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://CBMX/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://CBMX/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies-ScheduleOfEmployeeServiceShare-basedCompensationAllocationDetails Summary of Significant Accounting Policies - Schedule of Employee Service Share-based Compensation, Allocation (Details) Details 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://CBMX/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 22 false false R23.htm 00000023 - Disclosure - Cash and Short-Term Investments (Details Narrative) Sheet http://CBMX/role/CashAndShort-termInvestmentsDetailsNarrative Cash and Short-Term Investments (Details Narrative) Details http://CBMX/role/CashAndShort-termInvestmentsTables 23 false false R24.htm 00000024 - Disclosure - Cash and Short-Term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) Sheet http://CBMX/role/CashAndShort-termInvestments-ScheduleOfCashCashEquivalentsAndInvestmentsDetails Cash and Short-Term Investments - Schedule of Cash, Cash Equivalents and Investments (Details) Details 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) Sheet http://CBMX/role/FairValueMeasurements-FairValueAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) Details 25 false false R26.htm 00000026 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://CBMX/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://CBMX/role/StockholdersEquityTables 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://CBMX/role/StockholdersEquity-ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Details 27 false false R28.htm 00000028 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://CBMX/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://CBMX/role/CommitmentsAndContingencies 28 false false R29.htm 00000029 - Disclosure - Subsequent Events (Details Narrative) Sheet http://CBMX/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://CBMX/role/SubsequentEvents 29 false false All Reports Book All Reports cbmx-20170630.xml cbmx-20170630.xsd cbmx-20170630_cal.xml cbmx-20170630_def.xml cbmx-20170630_lab.xml cbmx-20170630_pre.xml true true ZIP 47 0001493152-17-008925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-008925-xbrl.zip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end